Elite Pharmaceuticals (ELTP) 10-K 21 Jun 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2019	Jun. 07, 2019	Sep. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ELITE PHARMACEUTICALS INC /NV/
Entity Central Index Key	0001053369
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Type	10-K
Document Period End Date	Mar. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 73,517,602
Entity Common Stock, Shares Outstanding		828,388,501

Consolidated Balance Sheets (Au

Consolidated Balance Sheets (Audited) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Current assets:
Cash	$ 2,277,643	$ 7,179,237
Accounts Receivable, net of allowance for doubtful accounts of $-0-, respectively	1,321,805	675,879
Inventory	4,515,723	4,898,001
Prepaid expenses and other current assets	741,371	949,284
Total current assets	8,856,542	13,702,401
Property and equipment, net of accumulated depreciation of $9,651,718 and $8,408,979, respectively	8,443,849	8,993,708
Intangible assets, net of accumulated amortization of $-0-, respectively	6,634,035	7,713,001
Other assets:
Restricted cash - debt service for NJEDA bonds	398,125	391,566
Security deposits	69,383	81,932
Total other assets	467,508	473,498
Total assets	24,401,934	30,882,608
Current liabilities:
Accounts Payable	1,375,347	1,658,137
Accrued expenses	3,713,601	1,788,571
Deferred revenue, current portion	1,013,333	1,013,333
Bonds payable, current portion, net of bond issuance costs	80,822	75,822
Loans payable, current portion	573,029	578,841
Customer Deposits	150,000
Total current liabilities	6,906,132	5,114,704
Long-term liabilities:
Deferred revenue, net of current portion	238,890	1,252,223
Bonds payable, net of current portion and bond issuance costs	1,427,315	1,508,134
Senior secured promissory note - related party	1,200,000	1,200,000
Loans payable, net current portion	699,269	623,020
Derivative financial instruments - warrants	2,487,830	2,667,871
Other long-term liabilities	46,402	41,144
Total long-term liabilities	6,099,706	7,292,392
Total liabilities	13,005,838	12,407,096
Mezzanine equity
Series J convertible preferred stock; par value $0.01; 50 shares authorized, 24.0344 issued and outstanding as of March 31, 2019; 50 shares authorized, 24.0344 issued and outstanding as of March 31, 2018	13,903,960	13,903,960
Shareholders' equity:
Common stock; par value $0.001; 995,000,000 shares authorized; 824,946,559 shares issued and 824,846,559 outstanding as of March 31, 2019; 802,626,761 shares issued and 802,526,761 shares outstanding as of March 31, 2018	824,949	802,629
Additional paid-in capital	148,780,087	146,602,502
Treasury stock; 100,000 shares as of March 31, 2019 and March 31, 2018; at cost	(306,841)	(306,841)
Accumulated deficit	(151,806,059)	(142,526,738)
Total shareholders' equity	(2,507,864)	4,571,552
Total liabilities, mezzanine equity and shareholders' equity	$ 24,401,934	$ 30,882,608

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Audited) (Parenthetical) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 0	$ 0
Accumulated depreciation	9,651,718	8,408,979
Accumulated amortization on intangible assets	$ 0	$ 0
Temporary equity, par value	$ 0.01	$ 0.01
Temporary equity, shares authorized	50	50
Temporary equity, shares issued	24.0344	24.0344
Temporary equity, shares outstanding	24.0344	24.0344
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	995,000,000	995,000,000
Common stock, shares issued	824,946,559	802,626,761
Common stock, shares outstanding	824,846,559	802,526,761
Treasury stock, shares	100,000	100,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Audited) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Manufacturing Fees	$ 5,387,696	$ 5,199,006
Licensing Fees	2,180,812	2,259,705
Total revenue	7,568,508	7,458,711
Cost of revenue	4,700,978	3,511,123
Gross Profit	2,867,530	3,947,588
Operating expenses:
Research and development	7,599,820	9,621,365
General and administrative	3,083,546	2,332,289
Non-cash compensation through issuance of stock options	136,369	244,753
Depreciation and amortization	1,206,495	800,460
Total operating expenses	12,026,230	12,998,867
Loss from operations	(9,158,700)	(9,051,279)
Other income (expense):
Interest expense and amortization of debt issuance costs	(369,173)	(335,498)
Change in fair value of derivative instruments	180,041	4,650,266
Interest income	21,461	17,510
(Loss) realized from transfer/discontinuance of intangible assets	(628,966)
Other (expense) income, net	(796,637)	4,332,278
(Loss) from operations before net benefit from sale of state net operating loss credits	(9,955,337)	(4,719,001)
Net benefit from sale of state net operating loss credits	676,016	1,045,829
Net (loss) attributable to common shareholders	$ (9,279,321)	$ (3,673,172)
Basic loss per share attributable to common shareholders	$ (0.01)	$ 0
Diluted loss per share attributable to common shareholders	$ (0.01)	$ (0.01)
Basic weighted average Common Stock outstanding	814,172,891	796,069,419
Diluted weighted average Common Stock outstanding	816,312,992	798,169,419

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Deficit) (Audited) - USD ($)	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Mar. 31, 2017	$ 928,034	$ 163,896,410	$ (306,841)	$ (138,853,566)	$ 25,664,037
Balance, Shares at Mar. 31, 2017	928,031,448		100,000
Net loss				(3,673,172)	(3,673,172)
Issuance of Common Stock pursuant to the exercise of cash warrants	$ 5,658	347,985			353,643
Issuance of Common Stock pursuant to the exercise of cash warrants, Shares	5,658,295
Common Stock issued in payment of consulting expense	$ 211	25,789			26,000
Common Stock issued in payment of consulting expense, Shares	211,392
Common Stock issued in payment of employee salaries	$ 2,461	302,539			305,000
Common Stock issued in payment of employee salaries, Shares	2,460,941
Common Stock issued in payment of Directors' Fees	$ 645	79,355			80,000
Common Stock issued in payment of Directors' Fees, Shares	645,496
Common Stock sold pursuant to the Lincoln Park purchase agreement	$ 17,819	1,982,059			1,999,878
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares	17,818,950
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement	$ 277	34,927			35,204
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares	277,009
Common Stock issued as commitment shares pursuant to the Lincoln Park purchase agreement	$ 5,541	914,191			919,732
Common Stock issued as commitment shares pursuant to the Lincoln Park purchase agreement, Shares	5,540,551
Costs associated with raising capital		(1,004,892)			(1,004,892)
Non-cash compensation through the issuance of employee stock options		244,753			244,753
Retirement of Common Stock	$ (158,017)	(20,220,614)			(20,378,631)
Retirement of Common Stock, Shares	(158,017,321)
Balance at Mar. 31, 2018	$ 802,629	146,602,502	$ (306,841)	(142,526,738)	4,571,552
Balance, Shares at Mar. 31, 2018	802,626,761		100,000
Net loss				(9,279,321)	(9,279,321)
Common Stock sold pursuant to the Lincoln Park purchase agreement	$ 22,034	2,041,502			2,063,536
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares	22,033,967
Common Stock issued as commitment shares pursuant to the Lincoln Park purchase agreement	$ 286	28,444			28,730
Common Stock issued as commitment shares pursuant to the Lincoln Park purchase agreement, Shares	285,831
Costs associated with raising capital		(28,730)			(28,730)
Non-cash compensation through the issuance of employee stock options		136,369			136,369
Balance at Mar. 31, 2019	$ 824,949	$ 148,780,087	$ (306,841)	$ (151,806,059)	$ (2,507,864)
Balance, Shares at Mar. 31, 2019	824,946,559		100,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Audited) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,279,321)	$ (3,673,172)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,256,917	996,406
Change in fair value of derivative financial instruments - warrants	(180,042)	(4,650,266)
Non-cash compensation accrued	1,581,250	925,000
Salaries & Directors fees satisfied by the issuance of Common Stock		385,000
Consulting expenses paid via the issuance of Common Stock		26,000
Non-cash compensation from the issuance of Common Stock and options	136,369	244,753
Non-cash rent expense and lease accretion	5,254	9,377
Non-cash Loss on sale and discontinuance of intangible assets	628,966
Change in operating assets and liabilities:
Accounts receivable	(545,926)	258,180
Inventory	382,278	1,517,965
Prepaid expenses and other current assets	23,826	(512,368)
Accounts payable, accrued expenses and other current liabilities	61,002	677,268
Deferred revenue and customer deposits	(863,333)	(1,013,334)
Net cash used in operating activities	(6,792,760)	(4,809,191)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(19,130)	(180,937)
Intellectual property costs		(93,910)
Proceeds from sale of intangible assets	350,000
Net cash from (used in) investing activities	330,870	(274,847)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of Common Stock to Lincoln Park Capital	2,092,265	1,999,878
Proceeds from cash warrant and options exercises		353,643
Payment of bond principal	(90,000)	(85,001)
Other loan proceeds (payments), net	(406,681)	(547,496)
Costs associated with raising capital	(28,729)	(49,957)
Net cash provided by financing activities	1,566,855	1,671,067
Net change in cash and restricted cash	(4,895,035)	(3,412,971)
Cash and restricted cash, beginning of period	7,570,803	10,983,774
Cash and restricted cash, end of period	2,675,768	7,570,803
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	226,455	135,146
Cash paid for taxes		5,500
Financing of equipment purchases and insurance renewal	686,968	755,594
Issuance of Senior Secured Promissory Note pursuant ANDA asset acquisition		1,200,000
Commitment shares issued to Lincoln Park Capital	28,729	954,936
Retirement of Common Stock pursuant to the issuance of Series J convertible preferred shares		$ 20,378,631

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview Elite Pharmaceuticals, Inc. (the “Company” or “Elite”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary Elite Laboratories, Inc. (“Elite Labs”) which was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. Elite Labs engages primarily in researching, developing and licensing proprietary orally administered, controlled-release drug delivery systems and products with abuse deterrent capabilities and the manufacture of generic, oral dose pharmaceuticals. The Company is equipped to manufacture controlled-release products on a contract basis for third parties and itself, if and when the products are approved. These products include drugs that cover therapeutic areas for pain, allergy, bariatric and infection. Research and development activities are done so with an objective of developing products that will secure marketing approvals from the United States Food and Drug Administration (“FDA”), and thereafter, commercially exploiting such products. Principles of Consolidation The accompanying audited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elite Laboratories, Inc. All significant intercompany accounts and transactions have been eliminated in consolidation. Going Concern At March 31, 2019, the Company had unrestricted cash balances totaling $2.3 million. The Company has incurred losses and negative cash flows from operations every year since its inception, including operating losses and negative overall cash flows of $9.1 million and $4.9 million for the year ended March 31, 2019, respectively. In addition, overall working capital, defined as current assets minus current liabilities decreased by approximately $6.6 million during the year ended March 31, 2019. Based on the foregoing, the Company has determined that there did appear to be evidence of substantial doubt of its ability to continue as a going concern. To continue as a going concern, the Company will need to do some or all of the following, without limitation: obtainment additional financing, increase sales of existing products, bring additional products in the pipe line to market and/or reduce expenses. the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements included herein do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Segment Information Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting The Company has determined that its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Applications (“ANDA”) and products whose marketing approvals were secured via a New Drug Application (“NDA”). ANDA products are referred to as generic pharmaceuticals and NDA products are referred to as branded pharmaceuticals. There are currently no intersegment revenues. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s audited consolidated financial statements. Please see note 17 for further details. Revenue Recognition The Company generates revenue from the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, commercialization of products either by license and the collection of royalties, or through the manufacture of formulations and the development of new products and the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations. The Company also generates revenue through its focus on the development of various types of drug products, including branded drug products which require NDAs. Under ASC 606, Revenue from Contacts with Customers Nature of goods and services The following is a description of the Company’s goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable: a) Manufacturing Fees The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if and when the products are approved. These products include products using controlled-release drug technology and products utilizing abuse deterrent technologies. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release and abuse deterrent pharmaceutical products. The Company recognizes revenue when the customer obtains control of the Company’s product based on the contractual shipping terms of the contract. Revenue on product are presented gross because the Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. b) License Fees The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of December 31, 2018. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer’s products occurs. Disaggregation of revenue In the following table, revenue is disaggregated by type of revenue generated by the Company and timing of revenue recognition. The table also includes a reconciliation of the disaggregated revenue with the reportable segments: For the year ended March 31, 2019 2018 NDA: Licensing fees $ 1,000,000 $ 1,000,000 Total NDA revenue 1,000,000 1,000,000 ANDA: Manufacturing fees $ 5,387,696 $ 5,199,006 Licensing fees 1,180,812 1,259,705 Total ANDA revenue 6,568,508 6,458,711 Total revenue $ 7,568,508 $ 7,458,711 Collaborative Arrangements Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808, Collaborative Arrangements ● The parties to the contract must actively participate in the joint operating activity; and ● The joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. The Company entered into a sales and distribution licensing agreement with Epic Pharma LLC, dated June 4, 2015 (the “ 2015 Epic License Agreement The Company entered into a Master Development and License Agreement with SunGen Pharma LLC dated August 24, 2016 (the “ SunGen Agreement Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market instruments. The Company places its cash and cash equivalents with high-quality, U.S. financial institutions and, to date has not experienced losses on any of its balances. Restricted Cash As of March 31, 2019, and 2018, the Company had $398,125 and $391,566 of restricted cash, respectively, related to debt service reserve in regard to the New Jersey Economic Development Authority (“ NJEDA Accounts Receivable Accounts receivable are comprised of balances due from customers, net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances. Inventory Inventory is recorded at the lower of cost or market on a specific identification by lot number basis. Long-Lived Assets The Company periodically evaluates the fair value of long-lived assets, which include property and equipment and intangibles, whenever events or changes in circumstances indicate that its carrying amounts may not be recoverable. Property and equipment are stated at cost. Depreciation is provided on the straight-line method based on the estimated useful lives of the respective assets which range from three to forty years. Major repairs or improvements are capitalized. Minor replacements and maintenance and repairs which do not improve or extend asset lives are expensed currently. Upon retirement or other disposition of assets, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is recognized in income. Intangible Assets The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. Costs to acquire indefinite lived intangible assets, such as costs related to ANDAs are capitalized accordingly. The Company tests its intangible assets for impairment at least annually (as of March 31st) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company’s segments; unanticipated competition; and slower growth rates. As of March 31, 2019, the Company did not identify any indicators of impairment. Please also see Note 5 for further details on intangible assets. Research and Development Research and development expenditures are charged to expense as incurred. Leases Lease agreements are evaluated to determine if they are capital leases meeting any of the following criteria at inception: (a) transfer of ownership; (b) bargain purchase option; (c) the lease term is equal to 75 percent or more of the estimated economic life of the leased property; or (d) the present value at the beginning of the lease term of the minimum lease payments, excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, including any profit thereon, equals or exceeds 90 percent of the excess of the fair value of the leased property to the lessor at lease inception over any related investment tax credit retained by the lessor and expected to be realized by the lessor. If at its inception a lease meets any of the four lease criteria above, the lease is classified by the Company as a capital lease; and if none of the four criteria are met, the lease is classified by the Company as an operating lease. Please also see the section titled “Recently Issued Accounting Pronouncements” regarding accounting standards relating to leases that will be implemented effective as of April 1, 2019. Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company operates in multiple tax jurisdictions within the United States of America. The Company remains subject to examination in all tax jurisdiction until the applicable statutes of limitation expire. As of March 31, 2019, a summary of the tax years that remain subject to examination in our major tax jurisdictions are: United States – Federal, 2014 and forward, and State, 2010 and forward. The Company did not record unrecognized tax positions for the years ended March 31, 2019 and 2018. Warrants and Preferred Shares The accounting treatment of warrants and preferred share series issued is determined pursuant to the guidance provided by ASC 470, Debt Distinguishing Liabilities from Equity Derivatives and Hedging Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation-Stock Compensation In accordance with the Company’s Director compensation policy and certain employment contracts, director’s fees and a portion of employee’s salaries are to be paid via the issuance of shares of the Company’s common stock, in lieu of cash, with the valuation of such share being calculated on a quarterly basis and equal to the simple average closing price of the Company’s common stock. Earnings (Loss) Per Share Applicable to Common Shareholders’ The Company follows ASC 260, Earnings Per Share The following is the computation of earnings (loss) per share applicable to common shareholders for the periods indicated: Years ended March 31, 2019 2018 Numerator Net loss attributable to common shareholders - basic $ (9,279,320 ) $ (3,673,172 ) Effect of dilutive instrument on net loss (180,042 ) (4,650,266 ) Net loss attributable to common shareholders - diluted $ (9,459,362 ) $ (8,323,438 ) Denominator Weighted average shares of common stock outstanding - basic 814,172,891 796,069,419 Dilutive effect of stock options, warrants and convertible securities 2,140,101 2,100,000 Weighted average shares of common stock outstanding - diluted 816,312,992 798,169,419 Net income (loss) per share Basic $ (0.01 ) $ (0.00 ) Diluted $ (0.01 ) $ (0.01 ) Fair Value of Financial Instruments ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows: ● Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 Inputs that are unobservable for the asset or liability. Measured on a Recurring Basis The following table presents information about our liabilities measured at fair value on a recurring basis as of March 31, 2019 and March 31, 2018, aggregated by the level in the fair value hierarchy within which those measurements fell: Amount at Fair Value Measurement Using Fair Value Level 1 Level 2 Level 3 March 31, 2019 Liabilities Derivative financial instruments - warrants $ 2,487,830 $ - $ - $ 2,487,830 March 31, 2018 Liabilities Derivative financial instruments - warrants $ 2,667,871 $ - $ - $ 2,667,871 See Note 12, for specific inputs used in determining fair value. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate their fair values because of the short maturity of these instruments. Based upon current borrowing rates with similar maturities the carrying value of long-term debt approximates fair value. Non-Financial Assets that are Measured at Fair Value on a Non-Recurring Basis Non-financial assets such as intangible assets, and property and equipment are measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets in the periods presented. Treasury Stock The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of shareholders’ equity (deficit). Recently Adopted Accounting Standards In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-01, Business Combinations: Clarifying the Definition of a Business In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ● ASU No. 2015-14, “ Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date” ● ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ; ● ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ● ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting ● ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606):Narrow-Scope Improvements and Practical Expedients ● ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers These ASUs have generally been codified in Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” Accounting Standards Codification Topic 605, “Revenue Recognition” The Company adopted ASC 606 on April 1, 2018 for all open contracts and related amendments as of such date, using the modified retrospective method. Under the modified retrospective method, results beginning on April 1, 2018 are presented under ASC 606, while the comparative prior period(s) results continue to be presented under ASC 605, based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded no change in its accumulated deficit at April 1, 2018, representing the cumulative impact of adopting ASC 606. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 , Restricted Cash (ASC 230): Statement of Cash Flows (“ASU No. 2016-18”). In May 2017, the FASB issued ASU No 2017-09 Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (ASC 842) In January 2017, the FASB issued ASU No 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (ASC 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In March 2019, the FASB issued ASU 2019-1, Leases (Topic 842) Codification Improvements ● Determining the fair value of the underlying asset by lessors that are not manufacturers or dealers (Issue 1); ● Presentation on the statement of cash flows—sales-type and direct financing leases (Issue 2), and ● Transition disclosures related to Topic 250, Accounting Changes and Error Corrections (Issue 3). The amendments in ASU 2019-1 amend Topic 842 and are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is evaluating the effect that this update will have on its consolidated financial statements and related disclosures. Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.

Asset Acquisition

Asset Acquisition	12 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
ASSET ACQUISITION	NOTE 2. ASSET ACQUISITION On May 15, 2017, Elite Laboratories, Inc., a wholly-owned subsidiary of the Company entered into an asset purchase agreement with Mikah Pharma, LLC (“Mikah” and/or the “Seller”), a related party, to acquire the Abbreviated New Drug Applications for Trimipramine Maleate Capsules and testing data, studies, and formulations created in connection therewith including but not limited to (i) the ANDA(s) (Trimipramine Maleate Capsules, 25, 50 and 100 mg ) (the “Product”), (ii) any correspondence with the United States Food and Drug Administration in Seller’s files with respect to the ANDA(s), (iii) the right of reference to the Drug Master Files, as set forth in the ANDA(s); (iv) the ANDA(s) Technology and Scientific Materials; (v) all rights to manufacture, sell or otherwise exploit any products resulting therefrom including all rights to revenues generated therefrom; and (vi) a royalty free limited license to use any ANDA(s) Technology and Scientific Materials which is common to the Product and any other product of Seller, but only for Buyer’s use in connection with the manufacture of any product (the “Purchased Assets”). Mikah is owned by Nasrat Hakim, the CEO, President and Chairman of the Board of the Company. For consideration of the purchased assets, the Company issued a Secured Promissory Note for the principal sum of $1,200,000 (see Note 8). The Company evaluated the acquisition of the purchased assets under ASC 805, Business Combinations ANDA acquisition costs $ 1,200,000 Total assets acquired $ 1,200,000

Inventory

Inventory	12 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
INVENTORY	NOTE 3. INVENTORY Inventory consisted of the following: March 31, March 31, Finished goods $ 575,699 $ 229,204 Work-in-progress 189,069 297,350 Raw materials 3,750,955 4,371,447 4,515,723 4,898,001 Less: Inventory reserve - - $ 4,515,723 $ 4,898,001

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 4. PROPERTY AND EQUIPMENT, NET Property and equipment consisted of the following: March 31, 2019 2018 Land, building and improvements $ 5,260,523 $ 5,260,524 Laboratory, manufacturing, warehouse and transportation equipment 12,078,340 11,715,805 Office equipment and software 373,601 176,965 Furniture and fixtures 383,103 249,393 18,095,567 17,402,687 Less: Accumulated depreciation (9,651,718 ) (8,408,979 ) $ 8,443,849 $ 8,993,708 Depreciation expense was $1,242,739 and $982,227for the years ended March 31, 2019 and 2018, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5. INTANGIBLE ASSETS The following tables summarize the Company’s intangible assets: March 31, 2019 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 465,684 $ - $ - $ - $ 465,684 ANDA acquisition costs Indefinite 7,247,317 - (1,078,966 ) - 6,168,351 $ 7,713,001 $ - $ (1,078,966 ) $ - $ 6,634,035 March 31, 2018 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 371,774 $ 93,910 $ - $ - $ 465,684 ANDA acquisition costs Indefinite 6,047,317 1,200,000 - - 7,247,317 $ 6,419,091 $ 1,293,910 $ - $ - $ 7,713,001 * Patent application costs were incurred in relation to the Company’s abuse deterrent opioid technology. Amortization of the patent costs will begin upon the issuance of marketing authorization by the FDA. Amortization will then be calculated on a straight-line basis through the expiry of the related patent(s). The following ANDA’s, with an aggregate carrying amount of $291,491 were discontinued during Fiscal 2019: ● 40227 – Phentermine 30mg capsules ● 40448 – Phentermine 30mg capsules ● 40460 – Phentermine 15mg capsules The following ANDA’s, with an aggregate carrying amount of $787,475 were transferred to Epic Pharma for cash consideration totaling $450,000: ● 40600 – Hydroxyzine 10mg ● 40602 – Hydroxyzine 25mg ● 40604 – Hydroxyzine 50mg The primary catalyst for the discontinuance and transfer of the above referenced ANDA’s was the FDA’s Generic Drug User Fee Amendment (“GDUFA”) fee structure, which provides for additional annual fees in excess of $1.1 million (as per the most current fee schedule published in August 2018) for entities that own in excess of 19 ANDA’s as of the annual April 15 measurement date. The ANDA’s approved by the FDA subsequent to the prior year’s measurement date, when added to those previously approved and owned by the Company, would have resulted in the Company owning more than 19 ANDA’s. Management conducted an evaluation of all ANDA’s held and the feasibility of incurring the additional GDUFA fees and identified the above ANDA’s as being not significant to the Company’s plans. The ANDA’s that were discontinued were duplicates of ANDA’s currently in commercial production and the ANDA’s sold to Epic Pharma were related to products that were not qualified for manufacture at the Northvale Facility. The aggregate carrying amount of the six ANDAs discontinued or transferred was $1,078,966 and the aggregate cash consideration received in relation to the transfer of ANDAs was $450,000, resulting in a realized loss on transfer/discontinuance of intangible assets of $628,966.

NJEDA Bonds

NJEDA Bonds	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
NJEDA BONDS	NOTE 6. NJEDA BONDS During August 2005, the Company refinanced a bond issue occurring in 1999 through the issuance of Series A and B Notes tax-exempt bonds (the "NJEDA Bonds" and/or "Bonds"). During July 2014, the Company retired all outstanding Series B Notes, at par, along with all accrued interest due and owed. In relation to the Series A Notes, the Company is required to maintain a debt service reserve. The debt serve reserve is classified as restricted cash on the accompanying audited consolidated balance sheets. The NJEDA Bonds require the Company to make an annual principal payment on September 1 st st st The following tables summarize the Company's bonds payable liability: March 31, March 31, Gross bonds payable NJEDA Bonds - Series A Notes $ 1,670,000 $ 1,760,000 Less: Current portion of bonds payable (prior to deduction of bond offering costs) (95,000 ) (90,000 ) Long-term portion of bonds payable (prior to deduction of bond offering costs) $ 1,575,000 $ 1,670,000 Bond offering costs $ 354,453 $ 354,453 Less: Accumulated amortization (192,591 ) (178,409 ) Bond offering costs, net $ 161,862 $ 176,044 Current portion of bonds payable - net of bond offering costs Current portions of bonds payable 95,000 $ 90,000 Less: Bonds offering costs to be amortized in the next 12 months (14,178 ) (14,178 ) Current portion of bonds payable, net of bond offering costs $ 80,822 $ 75,822 Long term portion of bonds payable - net of bond offering costs Long term portion of bonds payable 1,575,000 $ 1,670,000 Less: Bond offering costs to be amortized subsequent to the next 12 months (147,685 ) (161,866 ) Long term portion of bonds payable, net of bond offering costs $ 1,427,315 $ 1,508,134 Amortization expense was $14,178 for the years ended March 31, 2019 and 2018, respectively. Maturities of bonds for the next five years are as follows: Years ending March 31, Amount 2020 $ 95,000 2021 105,000 2022 110,000 2023 115,000 2024 125,000 Thereafter 1,120,000 $ 1,670,000

Loans Payable

Loans Payable	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
LOANS PAYABLE	NOTE 7. LOANS PAYABLE Loans payable consisted of the following: March 31, March 31, Equipment and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between July 2019 and December 2023 $ 1,272,298 $ 1,201,861 Less: Current portion of loans payable (573,029 ) (578,841 ) Long-term portion of loans payable $ 699,269 $ 623,020 The interest expense associated with the loans payable was $114,980 and $119,890 for the years ended March 31, 2019 and 2018, respectively. Loan principal payments for the next five years are as follows: Years ending March 31, Amount 2020 $ 573,029 2021 260,358 2022 239,802 2023 162,111 2024 36,998 $ 1,272,298

Related Party Secured Promissor

Related Party Secured Promissory Note with Mikah Pharma LLC	12 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY SECURED PROMISSORY NOTE WITH MIKAH PHARMA LLC	NOTE 8. RELATED PARTY SECURED PROMISSORY NOTE WITH MIKAH PHARMA LLC For consideration of the assets acquired on May 15, 2017, the Company issued a Secured Promissory Note (the "Note") to Mikah for the principal sum of $1,200,000. The Note matures on December 31, 2020 in which the Company shall pay the outstanding principal balance of the Note. Interest shall be computed on the unpaid principal amount at the per annum rate of ten percent (10%); provided, upon the occurrence of an Event of Default as defined within the Note, the principal balance shall bear interest from the date of such occurrence until the date of actual payment at the per annum rate of fifteen percent (15%). All interest payable hereunder shall be computed on the basis of actual days elapsed and a year of 360 days. Installment payments of interest on the outstanding principal shall be paid as follows: quarterly commencing August 1, 2017 and on November 1, February 1, May 1 and August 1 of each year thereafter. No principal or interest payments have been made on the Note since its issuance. All unpaid principal and accrued but unpaid interest shall be due and payable in full on the maturity date. The interest expense associated with the Note was $120,000 for the year ended March 31, 2019 and total accrued interest due and owing as of March 31, 2019 is $225,000.

Deferred Revenue

Deferred Revenue	12 Months Ended
	Mar. 31, 2019
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	NOTE 9. DEFERRED REVENUE Deferred revenues in the aggregate amount of $1,252,223 as of March 31, 2019, were comprised of a current component of $1,013,333 and a long-term component of $238,890. Deferred revenues in the aggregate amount of $2,265,557 as of March 31, 2018, were comprised of a current component of $1,013,333 and a long-term component of $1,252,223. These line items represent the unamortized amounts of a $200,000 advance payment received for a TAGI licensing agreement with a fifteen-year term beginning in September 2010 and ending in August 2025 and the $5,000,000 advance payment Epic Collaborative Agreement with a five-year term beginning in June 2015 and ending in May 2020. These advance payments were recorded as deferred revenue when received and are earned, on a straight-line basis over the life of the licenses. The current component is equal to the amount of revenue to be earned during the 12-month period immediately subsequent to the balance date and the long-term component is equal to the amount of revenue to be earned thereafter.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10. COMMITMENTS AND CONTINGENCIES Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company's consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Operating Leases – 135 Ludlow Ave. The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the " 135 Ludlow Ave. lease 135 Ludlow Ave. modified lease The 135 Ludlow Ave. modified lease includes an initial term, which expires on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021. The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company's manufacturing resources are in progress. Rent expense is recorded on the straight-line basis. Rents paid in excess is recognized as deferred rent. Rent expense under the 135 Ludlow Ave. modified lease for the years ended March 31, 2019 and 2018 was $219,638 and $219,636, respectively. Rent expense is recorded in general and administrative expense in the audited consolidated statements of operations. Deferred rent as of March 31, 2019 and 2018 was $13,022 And $9,702, respectively, and recorded as a component of other long-term liabilities. The tables below show the future minimum rental payments, exclusive of taxes, insurance and other costs, under the Ludlow Ave. lease: Years ending March 31, Amount 2020 $ 220,650 2021 225,063 2022 229,563 2023 234,156 2024 238,836 Thereafter 681,240 $ 1,829,508 The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, Asset Retirement and Environmental Obligations – Asset Retirement Obligations

Mezzanine Equity

Mezzanine Equity	12 Months Ended
	Mar. 31, 2019
Equity [Abstract]
MEZZANINE EQUITY	NOTE 11. MEZZANINE EQUITY Series I convertible preferred stock On February 6, 2014, the Company created the Series I Convertible Preferred Stock (“ Series I Preferred COD The COD for the Series I Preferred contained the following features: ● Conversion feature - the Series I Preferred Shares may be converted, at the option of the Holder, into the Company’s Common Stock at a stated conversion price of $0.07. ● Subsequent dilutive issuances - if the Company issues options at a price below the Conversion Price, then the Conversion Price will be reduced. ● Subsequent dividend issuances - if the Company issues Common Stock in lieu of cash in satisfaction of its dividend obligation on its Series C Certificate, the applicable Conversion Price of the Series I Preferred is adjusted. The Company has determined that the Series I Preferred host instrument was more akin to equity than debt and that the above financial instruments were clearly and closely related to the host instrument, with bifurcation and classification as a derivative liability being not required. Based on the Company’s review of the COD, the host instrument, the Series I Preferred Shares, was classified as mezzanine equity. The above identified embedded financial instruments: Conversion Feature, Subsequent Dilutive Issuances and Subsequent Dividend Issuances will not be bifurcated from the host and are therefore classified as mezzanine equity with the Series I Preferred. The Series I Preferred was carried at the maximum redemption value, with changes in this value charged to retained earnings or to additional paid-in capital in the absence of retained earnings. Changes in carrying value are also subtracted from net income (loss), (in a manner like the treatment of dividends paid on preferred stock), in arriving at net income (loss) available to common shareholders used in the calculation of earnings per share. Authorized, issued and outstanding shares, along with carrying value and change in value as of the periods presented are as follows: March 31, 2019 2018 Shares authorized 395.758 395.758 Shares outstanding - - Par value $ 0.01 $ 0.01 Stated value $ 100,000 $ 100,000 Conversion price $ 0.07 $ 0.07 Common Stock to be issued upon redemption - - Closing price on valuation date $ 0.10 $ 0.09 Carrying value of Series I convertible preferred stock $ - $ - Series J convertible preferred stock On April 28, 2017, the Company created the Series J Convertible Preferred Stock (“ Series J Preferred Series J COD The issued shares were pursuant to an Exchange Agreement with Nasrat Hakim, (“ Hakim Each Series J Preferred is convertible at the option of the holder into shares of common stock, that is the earlier of (i) the date that shareholder approval is obtained and the requisite corporate action has been effected regarding a Fundamental Transaction (as defined in the Series J COD); or (ii) not less than four years subsequent to the Original Issue Date (the date of the first issuance of any shares of the Series J Preferred Stock) (the “ Conversion Date Based on the current conversion price, the Series J Preferred is convertible into 158,017,321 shares of Common Stock. The conversion price is subject to the following adjustments: (i) stock dividends and splits, (ii) sale or grant of shares below the conversion price, (iii) pro rata distributions; or (iv) fundamental changes (merger, consolidation, or sale of all or substantially all assets). If upon any Conversion Date there is not a sufficient number of authorized shares of Common Stock (that are not issued, outstanding or reserved for issuance) available to effect the entire conversion of the then outstanding shares of Series J Preferred Stock and the then outstanding common stock purchase warrants issued in conjunction therewith (an “ Authorized Share Deficiency Solely during any period of time during which an Authorized Share Deficiency exists commencing on or after the second anniversary of the Original Issue Date (“ Dividend Commencement Date Dividend Entitlement Period Dividend Share Amount The holders of the Series J Preferred shall have voting rights on any matter presented to the shareholders of the Company for their action or consideration at any meeting of shareholders of the Company (or by written consent of shareholders in lieu of meeting). Each holder shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series J Preferred held by the holder are convertible as of the record date for determining the shareholders entitled to vote on such matter regardless of whether an Authorized Share Deficiency Exists. The Company has determined that the Series J Preferred host instrument was more akin to equity than debt and that the above identified conversion feature, subject to adjustments, was clearly and closely related to the host instrument, and accordingly bifurcation and classification of the conversion feature as a derivative liability was not required. The Company has accounted for the Series J Preferred as contingently redeemable preferred stock for which redemption is not probable. Accordingly, the Series J Preferred is presented in mezzanine equity based on their initial measurement amount (fair value), as required by ASC 480-10-S99, Distinguishing Liabilities from Equity – SEC Material The fair value of the Series J Preferred issued by the Company pursuant to the exchange agreement was calculated using a Monte Carlo Simulation of stock price and expected future behaviors related to shareholder approval provisions. The following are the key assumptions used in the Monte Carlo Simulation: April 28, Fair value of the Company's Common Stock $ 0.1521 Conversion price $ 0.1521 Number of Series J Preferred issued 24.0344 Fully diluted shares outstanding as of measurement date 923,392,780 Risk-free rate 2.30 % Volatility 90.00 % Shareholder approval threshold $ 0.1521 Probability of approval if ending stock price is greater than threshold - midpoint 82.50 % Probability of approval if ending stock price is greater than threshold - midpoint 17.50 % Trials 200,000 Authorized, issued and outstanding shares, along with carrying value and change in value as of the periods presented are as follows: March 31, March 31, Shares authorized 50.000 50.000 Shares outstanding 24.0344 24.0344 Par value $ 0.01 $ 0.01 Stated value $ 1,000,000 $ 1,000,000 Conversion price $ 0.1521 $ 0.1521 Common Stock to be issued upon conversion 158,017,321 158,017,321 Carrying value of Series J convertible preferred stock $ 13,903,960 $ 13,903,960

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	12 Months Ended
	Mar. 31, 2019
Derivative Financial Instruments Warrants Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS - WARRANTS	NOTE 12. DERIVATIVE FINANCIAL INSTRUMENTS – WARRANTS The Company evaluates and accounts for its freestanding instruments in accordance with ASC 815, Accounting for Derivative Instruments and Hedging Activities The Company issued warrants, with terms of seven to ten years, to various corporations and individuals, in connection with the sale of securities, loan agreements and consulting agreements. A summary of warrant activity is as follows: Year ended March 31, 2019 2018 Warrant Weighted Warrant Weighted Balance at beginning of year 79,008,661 $ 0.1521 9,379,219 $ 0.0625 Warrants granted pursuant to the issuance of Series J convertible preferred shares - $ - 79,008,661 $ 0.1521 Warrants exercised, forfeited and/or expired, net - $ - (9,379,219 ) $ 0.0625 Balance at end of year 79,008,661 $ 0.1521 79,008,661 $ 0.1521 Please note that all of the warrants issued prior to Fiscal 2018 were fully exercised, forfeited and/or expired on or before March 31, 2018. At March 31, 2018, the remaining warrants outstanding are held by Mr. Nasrat Hakim, the Company’s Chief Executive Officer in conjunction with the Exchange Agreement described below. The fair value of the warrants issued prior to Fiscal 2018, all was calculated using the Black-Scholes model and the following assumptions: March 31 Fair value of the Company's common stock $ 0.15 Volatility (based on the Company's historical volatility) 72.5% - 73.1 % Exercise price $ 0.0625 Estimated life (in years) 1.0 - 1.1 Risk free interest rate (based on 1-year treasury rate) 1.02% - 1.03 % On April 28, 2017, the Company entered into an exchange agreement (the “ Exchange Agreement Series J Preferred Securities The Series J Warrants are exercisable for a period of 10 years from the date of issuance, commencing on the earlier of (i) the date that Shareholder Approval is obtained, and the requisite corporate action has been effected; or (ii) April 28, 2020. The initial exercise price is $0.1521 per share and the Series J Warrants can be exercised for cash or on a cashless basis. The exercise price is subject to adjustment for any issuances or deemed issuances of common stock or common stock equivalents at an effective price below the then exercise price. Such exercise price adjustment feature prohibits the Company from being able to conclude the warrants are indexed to its own stock and thus such warrants are classified as liabilities and measured initially and subsequently at fair value. The Series J Warrants also provide for other standard adjustments upon the happening of certain customary events. The Series J Warrants are not exercisable during any period when an Authorized Share Deficiency exists and will expire on the expiry date, without regards to the existence of an Authorized Shares Deficiency (see Note 11). As of March 31, 2019, the Company does not have a sufficient number of unreserved authorized shares to effect the entire conversion of the Series J Preferred, therefore the Series J Warrants are not currently exercisable. Please also see Note 11. The fair value of the warrants issued by the Company pursuant to the issuance of Series J convertible preferred shares (79,008,661 warrant shares) was calculated using a Monte Carlo Simulation because of the probability assumptions associated with the Shareholder Approval provisions. The following are the key assumptions used in the Monte Carlo Simulation: March 31, March 31, Fair value of the Company's Common Stock $ 0.990 $ 0.100 Initial exercise price $ 0.1521 $ 0.1521 Number of common warrants 79,008,661 79,008,661 Fully diluted shares outstanding as of measurement date 824,946,559 791,516,930 Warrant term (in years) 8.08 9.08 Risk-free rate 2.35 % 2.72 % Volatility 90.00 % 90.00 % Shareholder approval threshold $ 0.1580 $ 0.1580 Probability of approval if ending stock price is greater than threshold - midpoint 82.50 % 82.50 % Probability of approval if ending stock price is greater than threshold - midpoint 17.50 % 17.50 % Trials 100,000 100,000 Fair value of derivative financial instruments - warrants $ 2,487,830 $ 2,667,871 The changes in warrants (Level 3 financial instruments) measured at fair value on a recurring basis for the year ended March 31, 2019 were as follows: Balance as of March 31, 2017 843,464 Fair value of warrants granted pursuant to the issuance of Series J convertible preferred shares 6,474,674 Change in fair value of derivative financial instruments - warrants (4,650,267 ) Balance as of March 31, 2018 $ 2,667,871 Change in fair value of derivative financial instruments - warrants (180,041 ) Balance as of March 31, 2019 $ 2,487,830

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	12 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
SHAREHOLDERS’ EQUITY (DEFICIT)	NOTE 13. SHAREHOLDERS’ EQUITY (DEFICIT) Lincoln Park Capital – April 10, 2014 Purchase Agreement On April 10, 2014, the Company entered into a Purchase Agreement (the “ Lincoln Park Purchase Agreement Purchase Agreement Registration Rights Agreement Lincoln Park Upon execution of the Purchase Agreement, the Company issued 1,928,641 shares of common stock to Lincoln Park pursuant to the Purchase Agreement as consideration for its commitment to purchase additional shares of common stock under that agreement and the Company is obligated to issue up to an additional 1,928,641 commitment shares to Lincoln Park pro rata as up to $40.0 million of common stock purchased by Lincoln Park. The 2014 LPC Purchase Agreement expired on June 1, 2017. During the term of the 2014 LPC Purchase Agreement, the Company sold an aggregate of 110.6 million shares to Lincoln Park, for aggregate gross proceeds of approximately $27.0 million. In addition, the Company issued an aggregate of 3.2 million commitment shares. Lincoln Park Capital – May 1, 2017 Purchase Agreement On May 1, 2017, the Company entered into a purchase agreement (the “ 2017 LPC Purchase Agreement 2017 LPC Registration Rights Agreement Under the terms and subject to the conditions of the 2017 LPC Purchase Agreement, the Company has the right to sell to and Lincoln Park is obligated to purchase up to $40 million in shares of common stock, subject to certain limitations, from time to time, over the 36-month period commencing on June 5, 2017. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 500,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase, increasing to up to 1,000,000 shares, depending upon the closing sale price of the common stock (such purchases, “ Regular Purchases In connection with the 2017 LPC Purchase Agreement, the Company issued to Lincoln Park 5,540,551 shares of common stock and are required to issue up to 5,540,551 additional shares of Common Stock pro rata as the Company requires Lincoln Park to purchase shares under the 2017 LPC Purchase Agreement over the term of the agreement. Lincoln Park has represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)). The Company sold the securities in reliance upon an exemption from registration contained in Section 4(a)(2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The 2017 LPC Purchase Agreement and the 2017 LPC Registration Rights Agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the 2017 LPC Purchase Agreement at any time, at no cost or penalty. Actual sales of shares of common stock to Lincoln Park under the 2017 LPC Purchase Agreement will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding for us and our operations. There are no trading volume requirements or, other than the limitation on beneficial ownership discussed above, restrictions under the 2017 LPC Purchase Agreement. Lincoln Park has no right to require any sales by the Company but is obligated to make purchases from the Company as directed in accordance with the 2017 LPC Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares. The net proceeds received by us under the 2017 LPC Purchase Agreement will depend on the frequency and prices at which the Company sell shares of common stock to Lincoln Park. A registration statement on form S-3 The Company, from time to time and at the Company’s sole discretion but no more frequently than every other business day, could direct Lincoln Park to purchase (a “ Regular Purchase In addition to Regular Purchases, on any business day on which the Company has properly submitted a Regular Purchase notice and the closing sale price is not below $0.15, the Company may purchase (an “ Accelerated Purchase In the case of both Regular Purchases and Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the business days used to compute the purchase price. Other than as set forth above, there are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control the timing and amount of any sales of the Company’s common stock to Lincoln Park. The Company’s sales of shares of common stock to Lincoln Park under the Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of common stock. The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, agreements, and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, without limitation, market conditions, the trading price of the Common Stock and determinations by the Company as to appropriate sources of funding for the Company and its operations. There are no trading volume requirements or restrictions under the Purchase Agreement. Lincoln Park has no right to require any sales by the Company but is obligated to make purchases from the Company as it directs in accordance with the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Company shares. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. During the year ended March 31, 2019, a total of 22,033,967 shares were sold to Lincoln Park pursuant to the 2017 LPC Agreement for net proceeds totaling $2,063,541. In addition, 285,831 shares were issued to Lincoln Park as additional commitment shares, pursuant to the 2017 LPC Agreement. During the year ended March 31, 2018, a total of 17,818,950 shares were sold to Lincoln Park pursuant to the 2017 LPC Agreement for net proceeds totaling $1,999,878. In addition, 5,540,551 shares were issued to Lincoln Park as initial commitment shares and 277,009 shares were issued to Lincoln Park as additional commitment shares, pursuant to the 2017 LPC Agreement. Summary of Common Stock Activity During the years ended March 2019 and 2018, the Company issued a total of 32,612,634 and 216,487,096 shares of Common Stock, respectively, with such issuances of Common Stock being summarized as follows: Years ended March 31, 2019 2018 Common Stock sold pursuant to the Lincoln Park Capital Purchase Agreements, with net proceeds of such shares totaling $2,063,541 and $1,999,878 for the years ended March 31, 2019 and 2018, respectively. 22,033,967 17,818,950 Common Stock issued as initial and additional commitment shares pursuant to the Lincoln Park Capital Purchase Agreements 285,831 5,817,560 Common Stock issued in payment of Director’s fees totaling $0 and $80,000 for the years ended March 31, 2019 and 2018, respectively. - 645,496 Common Stock issued in payment of employee salaries totaling $0 and $305,000 for the years ended March 31, 2019 and 2018, respectively. - 2,460,941 Common Stock issued in payment of consulting expenses totaling $0 and $26,000 for the years ended March 31, 2019 and 2018, respectively. - 211,392 Common Stock issued pursuant to the exercise of cash warrants - 5,658,295 Common Stock Issued during the fiscal year 22,319,798 32,612,634 Retirement of Common Stock during the fiscal year - (158,017,321 ) Common Stock issued as of March 31, 2019 and 2018, respectively 824,946,559 802,626,761

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	NOTE 14. STOCK-BASED COMPENSATION Part of the compensation paid by the Company to its Directors and employees consists of the issuance of common stock or via the granting of options to purchase common stock. Stock-based Director Compensation The Company’s Director compensation policy was instituted in October 2009 and further revised in January 2016, includes provisions that a portion of director’s fees are to be paid via the issuance of shares of the Company’s common stock, in lieu of cash, with the valuation of such shares being calculated on quarterly basis and equal to the average closing price of the Company’s common stock. During the year ended March 31, 2019, the Company accrued a total of 793,617 shares of Common Stock as being due and owing in relation to director compensation totaling $75,000 earned and accrued during the period January 1, 2018 through March 31, 2019, and consisting of 656,827 shares accrued for director compensation totaling $60,000 for the 12 months ended March 31, 2019 and 136,790 shares accrued for director compensation totaling $15,000 for the 3 months ended March 31, 2018. Issuance of these shares has been deferred to an undetermined date. During the years ended March 31, 2019 and 2018, the Company issued 645,496 and 334,295 shares of its Common Stock, respectively, relating to director compensation totaling $80,000 and $73,361, for each year, respectively. Stock-based Employee Compensation Employment contracts with the Company’s President and Chief Executive Officer, Chief Financial Officer and certain other employees includes provisions for a portion of each employee’s salaries to be paid via the issuance of shares of the Company’s common stock, in lieu of cash, with the valuation of such shares being calculated on a quarterly basis and equal to the average closing price of the Company’s common stock. During the year ended March 31, 2019, the Company accrued a total of 4,034,219 shares of common stock as being due and owing to certain employees, exclusive of the Company’s Chief Executive Officer and relating to accrued salaries in the aggregate amount of $381,250 earned but not paid during the period January 1, 2018 through March 31, 2019 and consisting of 3,338,871 shares accrued for salaries totaling $305,000 for the 12 months ended March 31, 2019 and 695,348 shares accrued for salaries totaling $76,250 for the 3 months ended March 31, 2018. Issuance of these shares has been deferred to an undetermined date. During the year ended March 31, 2019, the Company accrued a total of 10,648,343 shares of common stock as being due and owing to its Chief Executive Officer and relating to accrued salaries in the aggregate amount of $1,125,000 earned, but not paid during the period January 1, 2017 through March 31, 2019. Of this amount, 5,473,559 shares was accrued for salaries totaling $500,000 for the 12 months ended March 31, 2019, 4,329,661 shares was accrued for salaries totaling $500,000 for the 12 months ended March 31, 2018 and 845,083 shares was accrued for salaries totaling $125,000 for the 3 month period ended March 31, 2017. Issuance of these shares has been deferred to an undetermined date. As of March 31, 2019, the Company owes its President and Chief Executive Officer, Chief Financial Officer and certain other employees, a total of approximately 14.7 million shares of Common Stock in payment of salaries and fees totaling 1.5 million due and owing, inclusive of salaries earned by the Company’s Chief Executive Officer, as described in the paragraph above. Issuance of these shares of common stock has been deferred to an undetermined date. Options Under its 2014 Stock Option Plan and prior options plans, the Company may grant stock options to officers, selected employees, as well as members of the Board of Directors and advisory board members. All options have generally been granted at a price equal to or greater than the fair market value of the Company’s Common Stock at the date of the grant. Generally, options are granted with a vesting period of up to three years and expire ten years from the date of grant. Weighted Average Shares Weighted Average Exercise Remaining Contractual Aggregate Intrinsic Options Price (in years) Value Outstanding at March 31, 2017 6,737,667 $ 0.20 6.7 $ 258,747 Granted 640,000 0.16 Forfeited and expired - - Exercised (759,667 ) 0.56 Outstanding at March 31, 2018 6,618,000 $ 0.16 6.1 $ 90,390 Granted - Forfeited and expired (460,000 ) Exercised - Outstanding at March 31, 2019 6,158,000 $ 0.15 5.0 $ 87,330 Exercisable at March 31, 2019 5,635,002 $ 0.14 4.7 87,330 The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company common stock as of March 31, 2019 and 2018 was $0.10 and $0.10. The fair value of the options was calculated using the Black-Scholes model and the following assumptions: March 31, 2019 2018 Volatility (based on the Company's historical volatility) n/a 121% - 123 % Exercise price n/a $ 0.09 - 0.24 Estimated term (in years) n/a 10 Risk free interest rate (based on 1-year treasury rate) n/a 2.2% - 2.4 % Forfeiture rate n/a 0.0% - 20.1 % Fair value of options granted n/a $ 79,215 Non-cash compensation through issuance of stock options n/a $ 244,753

Sale of New Jersey State Net Op

Sale of New Jersey State Net Operating Losses	12 Months Ended
	Mar. 31, 2019
Sale of New Jersey State Net Operating Losses [Abstract]
SALE OF NEW JERSEY STATE NET OPERATING LOSSES	NOTE 15. SALE OF NEW JERSEY STATE NET OPERATING LOSSES During the year ended March 31, 2019, Elite Labs, a wholly owned subsidiary of Elite, received final approval from the New Jersey Economic Development Authority for the sale of net tax benefits of $296,883 relating to New Jersey net operating losses and net tax benefits of $376,133 relating to R&D tax credits. The Company sold the net tax benefits approved for sale at a transfer price equal to ninety-two cents for every benefit dollar for total proceeds of $619,175. During the year ended March 31, 2018, Elite Labs, a wholly owned subsidiary of Elite, received final approval from the New Jersey Economic Development Authority for the sale of net tax benefits of $439,313 relating to New Jersey net operating losses and net tax benefits of $606,516 relating to R&D tax credits. The Company sold the net tax benefits approved for sale at a transfer price equal to ninety-two cents for every benefit dollar for total proceeds of $1,045,829.

Concentrations and Credit Risk

Concentrations and Credit Risk	12 Months Ended
	Mar. 31, 2019
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND CREDIT RISK	NOTE 16. CONCENTRATIONS AND CREDIT RISK Revenues Four customers accounted for substantially all the Company's revenues for the year ended March 31, 2019. These four customers accounted for approximately 57%, 22%, 9% and 8% of revenues each, respectively. Four customers accounted for substantially all the Company's revenues for the year ended March 31, 2018. These four customers accounted for approximately 52%, 24%, 15% and 8% of revenues each, respectively. Accounts Receivable Four customers accounted for substantially all the Company's accounts receivable as of March 31, 2019. These four customers accounted for approximately 38%, 34%, 19%, and 4% of accounts receivable as of March 31, 2019. Four customers accounted for substantially all the Company's accounts receivable as of March 31, 2018. These four customers accounted for approximately 52%, 14%, 12%, and 11% of accounts receivable as of March 31, 2018. Purchasing Three suppliers accounted for more than 60% of the Company's purchases of raw materials for year ended March 31, 2019. These three suppliers accounted for approximately 35%, 17% and 11% of purchases each, respectively. Three suppliers accounted for more than 60% of the Company's purchases of raw materials for year ended March 31, 2018. These three suppliers accounted for approximately 29%, 27% and 5% of purchases each, respectively.

Segment Results

Segment Results	12 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
SEGMENT RESULTS	NOTE 17. SEGMENT RESULTS FASB ASC 280-10-50 requires use of the “management approach” model for segment reporting. The management approach is based on the way a company’s management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company has determined that its reportable segments are Abbreviated New Drug Applications (“ANDA”) for generic products and New Drug Applications (“NDA”) for branded products. The Company identified its reporting segments based on the marketing authorization relating to each and the financial information used by its chief operating decision maker to make decisions regarding the allocation of resources to and the financial performance of the reporting segments. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s audited consolidated financial statements. The following represents selected information for the Company’s reportable segments: Years ended March 31, 2019 2018 Revenue by Segment ANDA $ 6,568,508 $ 6,458,711 NDA 1,000,000 1,000,000 $ 7,568,508 $ 7,458,711 Years ended March 31, 2019 2018 Operating Income (Loss) by Segment ANDA $ (4,361,649 ) $ (1.827,943 ) NDA 122,961 (3,019,859 ) $ (4,238,688 ) $ (4,847,802 ) The table below reconciles the Company’s operating income (loss) by segment to income from operations before provision for income taxes as reported in the Company’s audited consolidated statements of operations. Years ended March 31, 2019 2018 Operating loss by segment $ (4,238,688 ) $ (4,847,802 ) Corporate unallocated costs (2,683,720 ) (2,234,264 ) Interest income 8,448 17,510 Interest expense and amortization of debt issuance costs (369,174 ) (335,498 ) Depreciation and amortization expense (1,206,495 ) (800,460 ) Significant non-cash items (1,645,750 ) (1,168,753 ) Change in fair value of derivative instruments 180,042 4,650,266 Income (loss) from operations before the benefit from sale of state net operating loss credits $ (9,955,337 ) $ (4,719,001 )

Collaborative Agreement with Ep

Collaborative Agreement with Epic Pharma LLC	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
COLLABORATIVE AGREEMENT WITH EPIC PHARMA LLC	NOTE 18. COLLABORATIVE AGREEMENT WITH EPIC PHARMA LLC On June 4, 2015, the Company entered into the 2015 Epic License Agreement, which provides for the exclusive right to market, sell and distribute, by Epic Pharma LLC (" Epic") Epic Exclusivity Period In June 2015, Elite received non-refundable payments totaling $5.0 million from Epic for the exclusive right to product development sales and distribution of SequestOx™ pursuant to the Epic Collaborative Agreement, under which it agreed to not permit marketing or selling of SequestOx™ within the United States of America to any other party. Such exclusive rights are considered a significant deliverable element of the Epic Collaborative Agreement pursuant to ASC 605-25, Revenue Recognition – Multiple Element Arrangements In addition, in January 2016, a New Drug Application for SequestOx™ was filed, thereby earning the Company a non-refundable $2.5 million milestone, pursuant to the 2015 Epic License Agreement. The filing of this NDA represents a significant deliverable element as defined within the Epic Collaborative pursuant to ASC 605-25, Revenue Recognition – Multiple Element Arrangements To date, the Company received payments totaling $7.5 million pursuant to the 2015 Epic License Agreement, with all amounts being non-refundable. An additional $7.5 million is due upon approval by the FDA of the NDA filed for SequestOx™, and license fees based on commercial sales of SequestOx™. Revenues relating to these additional amounts due under the 2015 Epic License Agreement will be recognized as the defined elements are completed and collectability is reasonably assured. Please note that on July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx™ NDA is complete and the application is not ready for approval in its present form. On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for or SequestOx™. The mean Tmax (the amount of time that a drug is present at the maximum concentration in serum) of SequestOx TM TM The 2015 Epic License Agreement expires on June 4, 2020, and Epic has previously advised the Company of their desire to extend this agreement. While discussions are ongoing, they are directly correlated to the regulatory status of SequestOx™. Furthermore, there can be no assurances that the parties will reach mutual agreement to extend the term of this agreement and no assurances that the terms and conditions of the agreement will be similar in all material aspects in the event that the agreement is extended by mutual consent of the parties. Non-receipt by the Company of the remaining $7.5 million milestone will have a material adverse effect on the Company's financial condition.

Collaborative Agreement with Su

Collaborative Agreement with Sungen Pharma LLC	12 Months Ended
	Mar. 31, 2019
Collaborative Agreement with Sungen Pharma LLC [Abstract]
COLLABORATIVE AGREEMENT WITH SUNGEN PHARMA LLC	NOTE 19. COLLABORATIVE AGREEMENT WITH SUNGEN PHARMA LLC On August 24, 2016, the Company entered into the SunGen Agreement. The SunGen Agreement provides that Elite and SunGen Pharma LLC will engage in the research, development, sales, and marketing of four generic pharmaceutical products. Two of the products are classified as CNS stimulants (the " CNS Products Under the terms of the SunGen Agreement, Elite and SunGen will share in the responsibilities and costs in the development of these products and will share in the profits from sales of the Products. Upon approval, the know-how and intellectual property rights to the products will be owned jointly by Elite and SunGen. SunGen shall have the exclusive right to market and sell the Beta Blocker Products using SunGen's label and Elite shall have the exclusive right to market and sell the CNS Products using Elite's label. Elite will manufacture and package all four products on a cost-plus basis. On December 1, 2016 and July 24, 2017, Elite Labs and SunGen executed an amendment to the parties' 2016 Development and License Agreement (the " Amended Agreement Under the terms of the Amended Agreement, Elite and SunGen will share in the responsibilities and costs in the development of these products and will share substantially in the profits from sales of the products. Upon approval, the know-how and intellectual property rights to the products will be owned jointly by Elite and SunGen. Three products will be owned jointly by Elite and SunGen; three shall be owned by SunGen while Elite shall have the marketing rights once the products are approved by the FDA; and two shall be owned by Elite while SunGen shall have the marketing rights once the products are approved by the FDA. Elite will manufacture and package all eight products on a cost-plus basis. On December 10, 2018, the Company received approval from the FDA for an ANDA filed for a generic version of Adderall®, an immediate-release mixed salt of a single entity amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5mg, 7.5mg. 10mg, 12.5mg, 15mg, 20mg, and 30mg tablets. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. This approval represents the first FDA approval received for a product co-developed with SunGen under the SunGen Agreement. The first commercial shipment of this product occurred in April 2019. The product is currently marketed by Lannett Company Inc. ("Lannett") under license granted pursuant a strategic marketing alliance dated March 11, 2019 ("the Lannett Alliance"). On May 24, 2018, the Company filed an ANDA with the FDA for a generic version of an extended release CNS stimulant. The ANDA represents the second filing for a product co-developed with SunGen under the SunGen Agreement. This product will also be marketed by Lannett pursuant to the Lannett Alliance. On January 3, 2019, the Company filed an ANDA with the FDA for a generic version of an antibiotic product. The ANDA represents the third filing for a product co-developed with SunGen under the SunGen Agreement. There can be no assurances that any of these products, even those for which ANDAs have been filed, will receive marketing authorization and achieve commercialization within a reasonable time period, or at all. In addition, even if marketing authorization is received, including the product for which such marketing authorization has already been received, there can be no assurances that there will be future revenues of profits, or that any such future revenues or profits would be in amounts that provide adequate return on the significant investments made to secure these marketing authorizations.

Related Party Transaction Agree

Related Party Transaction Agreements With Epic Pharma LLC	12 Months Ended
	Mar. 31, 2019
Epic Pharma Llc [Member]
RELATED PARTY TRANSACTION AGREEMENTS WITH EPIC PHARMA LLC	NOTE 20. RELATED PARTY TRANSACTION AGREEMENTS WITH EPIC PHARMA LLC The Company has entered into two agreements with Epic which constitute agreements with a related party due to the management of Epic including a member on our Board of Directors at the time such agreements were executed. On June 4, 2015, the Company entered into the 2015 Epic License Agreement (please see Note 18 above). The 2015 Epic License Agreement includes milestone payments totaling $10 million upon the filing with and approval of a New Drug Application (“NDA”) with the FDA. The Company has determined these milestones to be substantive, with such assessment being made at the inception of the 2015 Epic License Agreement, and based on the following: ● The Company’s performance is required to achieve each milestone; and ● The milestones will relate to past performance, when achieved; and ● The milestones are reasonable relative to all of the deliverables and payment terms within the 2015 Epic License Agreement After marketing authorization is received from the FDA, Elite will receive a license fee which is based on profits achieved from the commercial sales of ELI-200. On January 14, 2016, the Company filed an NDA with the FDA for SequestOx™, thereby earning a $2.5 million milestone pursuant to the 2015 Epic License Agreement. The Company has received payment of this amount from Epic. An additional $7.5 million is due upon approval by the FDA of the NDA filed for SequestOx™. Please note that on July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx™ NDA is complete and the application is not ready for approval in its present form. On December 21, 2016, the Company met with the FDA for an end-of-review meeting to discuss steps that it could take to obtain approval of SequestOx™. Based on this and the meeting minutes received from the FDA on January 23, 2017, the Company formulated a plan to address the issues cited by the FDA in the CRL, with such plan including, without limitation, modifying the SequestOx™ formulation, conducting bioequivalence and bioavailability fed and fasted studies, comparing the modified formulation to the original formulation. On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for SequestOx™. This study resulted in a mean Tmax of 4.6 hours, with a range of 0.5 hour to 12 hours and a mean Tmax of the comparator, Roxicodone ® On October 2, 2013, Elite executed the Epic Pharma Manufacturing and License Agreement (the “Epic Generic Agreement”). The Epic Generic Agreement, which expired on October 2, 2018 granted rights to Epic to manufacture twelve generic products whose ANDA’s are owned by Elite, and to market, in the United States and Puerto Rico, six of these products on an exclusive basis, and the remaining six products on a non-exclusive basis. These products were to be manufactured at Epic, with Epic being responsible for the manufacturing site transfer supplements that are a prerequisite to each product being approved for commercial sale. In addition, Epic was to be responsible for all regulatory and pharmacovigilance matters, as well as all marketing and distribution activities. Elite has no further obligations or deliverables under the Epic Generic Agreement. Pursuant to the Epic Generic Agreement, Elite was to receive $1.8 million, payable in increments that require the commercialization of all six exclusive products if the full amount is to be received, plus license fees equal to a percentage that is not less than 50% and not greater than 60% of profits achieved from commercial sales of the products, as defined in the Epic Generic Agreement. The Epic Generic Agreement expired on October 2, 2018 with Epic launching four of the six exclusive products and Elite collecting $1.0 million of the total $1.8 million fee. The 2015 Epic License Agreement contains license fees that will be earned and payable to the Company, after the FDA has issued marketing authorization(s) for the related product(s). License fees are based on commercial sales of the products achieved by Epic and calculated as a percentage of net sales dollars realized from such commercial sales. Net sales dollars consist of gross invoiced sales less those costs and deductions directly attributable to each invoiced sale, including, without limitation, cost of goods sold, cash discounts, Medicaid rebates, state program rebates, price adjustments, returns, short date adjustments, charge backs, promotions, and marketing costs. The rate applied to the net sales dollars to determine license fees due to the Company is equal to an amount negotiated and agreed to by the parties to each agreement, with the following significant factors, inputs, assumptions, and methods, without limitation, being considered by either or both parties: ● Assessment of the opportunity for each product in the market, including consideration of the following, without limitation: market size, number of competitors, the current and estimated future regulatory, legislative, and social environment for abuse deterrent opioids and the other generic products to which the underlying contracts are relevant; ● Assessment of various avenues for monetizing SequestOx™ and the twelve ANDA’s owned by the Company, including the various combinations of sites of manufacture and marketing options; ● Elite’s resources and capabilities with regards to the concurrent development of abuse deterrent opioids and expansion of its generic business segment, including financial and operational resources required to achieve manufacturing site transfers for twelve approved ANDA’s; ● Capabilities of each party with regards to various factors, including, one or more of the following: manufacturing, marketing, regulatory and financial resources, distribution capabilities, ownership structure, personnel, assessments of operational efficiencies and entity stability, company culture and image; ● Stage of development of SequestOx™ and manufacturing site transfer and regulatory requirements relating to the commercialization of the generic products at the time of the discussions/negotiations, and an assessment of the risks, probability, and time frames for achieving marketing authorizations from the FDA for each product. ● Assessment of consideration offered; and ● Comparison of the above factors among the various entities with whom the Company was engaged in discussions relating to the commercialization of SequestOx™ and the manufacture/marketing of the twelve generics related to the Epic Generic Agreement. This transaction is not to be considered as an arms-length transaction. Please also note that, effective April 7, 2016, all Directors on the Company’s Board of Directors that were also owners/managers of Epic had resigned as Directors of the Company and all current members of the Company’s Board of Directors have no relationship to Epic. Accordingly, Epic no longer qualifies as a party that is related to the Company.

Manufacturing, License and Deve

Manufacturing, License and Development Agreements	12 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
MANUFACTURING, LICENSE AND DEVELOPMENT AGREEMENTS	NOTE 21. MANUFACTURING, LICENSE AND DEVELOPMENT AGREEMENTS The Company has entered into the following active agreements: ● License agreement with Precision Dose, dated September 10, 2010 (the “Precision Dose License Agreement”); ● Development and License Agreement with SunGen (the “SunGen Agreement”); ● Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc. USA dated May 29, 2018 (the “Glenmark Alliance”); ● Strategic Marketing Alliance with Lannett Company. Inc. dated March 11, 2019 (the “Lannett-SunGen Product Alliance”) ● Strategic Marketing Alliance with Lannett Company. Inc. dated April 9, 2019 (the “Lannett-Elite Product Alliance”) The Precision Dose Agreement provides for the marketing and distribution, by Precision Dose and its wholly owned subsidiary, TAGI Pharma, of Phentermine 37.5mg tablets (launched in April 2011), Phentermine 15mg capsules (launched in April 2013), Phentermine 30mg capsules (launched in April 2013), Hydromorphone 8mg tablets (launched in March 2012), Naltrexone 50mg tablets (launched in September 2013) and certain additional products that require approval from the FDA which has not been received. Precision Dose will have the exclusive right to market these products in the United States and Puerto Rico and a non-exclusive right to market the products in Canada. Pursuant to the Precision Dose License Agreement, Elite received $200k at signing, and is receiving milestone payments and a license fee which is based on profits achieved from the commercial sale of the products included in the agreement. Revenue from the $200k payment made upon signing of the Precision Dose Agreement is being recognized over the life of the Precision Dose Agreement. The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 & 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts. These milestones have been determined to be substantive, with such determination being made by the Company after assessments based on the following: ● The Company’s performance is required to achieve each milestone; and ● The milestones will relate to past performance, when achieved; and ● The milestones are reasonable relative to all of the deliverables and payment terms within the Precision Dose License Agreement. The license fees provided for in the Precision Dose Agreement are calculated as a percentage of net sales dollars realized from commercial sales of the related products. Net sales dollars consist of gross invoiced sales less those costs and deductions directly attributable to each invoiced sale, including, without limitation, cost of goods sold, cash discounts, Medicaid rebates, state program rebates, price adjustments, returns, short date adjustments, charge backs, promotions, and marketing costs. The rate applied to the net sales dollars to determine license fees due to the Company is equal to an amount negotiated and agreed to by the parties to the Precision Dose License Agreement, with the following significant factors, inputs, assumptions, and methods, without limitation, being considered by either or both parties: ● Assessment of the opportunity for each generic product in the market, including consideration of the following, without limitation: market size, number of competitors, the current and estimated future regulatory, legislative, and social environment for each generic product, and the maturity of the market; ● Assessment of various avenues for monetizing the generic products, including the various combinations of sites of manufacture and marketing options; ● Capabilities of each party with regards to various factors, including, one or more of the following: manufacturing resources, marketing resources, financial resources, distribution capabilities, ownership structure, personnel, assessment of operational efficiencies and stability, company culture and image; ● Stage of development of each generic product, all of which did not have FDA approval at the time of the discussions/negotiations and an assessment of the risks, probability, and time frame for achieving marketing authorizations from the FDA for the products; ● Assessment of consideration offered by Precision and other entities with whom discussions were conducted; and, ● Comparison of the above factors among the various entities with whom the Company was engaged in discussions relating to the commercialization of the generic products. The SunGen Agreement provides for the research, development, sales and marketing of eight generic pharmaceutical products. Two of the products are classified as CNS stimulants (the “CNS Products”), two of the products are classified as beta blockers and the remaining four products consist of antidepressants, antibiotics and antispasmodics. To date, the Company has filed ANDAs with the FDA for the two CNS Products and one antibiotic identified in the SunGen Agreement. The Company received FDA approval of the ANDA filed for the first CNS Product in December 2018 and achieved commercial launch in April 2019, with such product being marketed pursuant to the Lannett Alliance. Under the terms of the SunGen Agreement, Elite and SunGen will share in the responsibilities and costs in the development of these products and will share substantially in the profits from sales. Upon approval, the know-how and intellectual property rights to the products will be owned jointly by Elite and SunGen. Three of the eight products will be jointly owned, three products will be owned by SunGen, with Elite having exclusive marketing rights and the remaining two products will be owned by Elite, with SunGen having exclusive marketing rights. Elite will manufacture and package all eight products on a cost-plus basis. The Glenmark Alliance, provides for the manufacture by Elite and marketing by Glenmark of identified generic products under license from Elite. In addition to the purchase prices for the products, Elite will receive license fees well in excess of 50% of gross profits. Gross profit is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. Glenmark will have semi-exclusive marketing rights to the ANDA approved generic product, phendimetrazine 35mg tablets, and exclusive marketing rights to generic Methadone HCl. Collectively, the brand products and their generic equivalents had total annual sales of approximately $33.6 million in 2017, according to Quintiles IMS Health data. The Agreement has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Glenmark to terminate with regard to a product on at least three months’ prior written notice if it determines to stop marketing and selling such product, and it permits Elite to terminate with regard to a product if at any time after the first twelvemonths from the first commercial sale, the average license fee paid by Glenmark for such product is less than $100,000 for a six-month sales period. Pursuant to Lannett-SunGen Product Alliance with Lannett Company Inc. (“Lannett”), Lannett will be the exclusive U.S. marketer and distributor for two generic products co-developed and co-owned by Elite and SunGen – Amphetamine IR Tablets and a second product which is an extended release CNS stimulant that is currently under review by the FDA. Elite will manufacture and Lannett will purchase the products from Elite and then sell and distribute them. In addition to the purchase prices for the products, Elite will receive license fees in excess of 50% of net profits, which will be shared equally with SunGen, pursuant to the SunGen Agreement. The Lannett-SunGen Product Alliance has an initial term of three years and automatically renews for one year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months’ prior written notice, and it permits Elite or Lannett to terminate with regard to a product if at anytime after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period. In addition to manufacturing fees and license fees, Lannett will also pay a milestone, of $750,000 upon commercial launch of the extended release CNS stimulant product that is currently under review by the FDA. This milestone payment will be shared equally by Elite and SunGen, pursuant to the SunGen Agreement. The first commercial shipment of Amphetamine IR Tablets, a generic version of Adderall ® Pursuant to the Lannett-Elite Product Alliance, Lannett will be the exclusive U.S. marketer and distributor for Dantrolene Capsules. Elite will manufacture and Lannett will purchase Dantrolene Capsules from Elite and then sell and distribute them. In addition to the purchase prices for the products, Elite will receive license fees in excess of 50% of net profits. Net profits is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. The Lannett-Elite Product Alliance has an initial term of three years and automatically renews for one year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months’ prior written notice and it permits Elite or Lannett to terminate with regard to a product if at anytime after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period.

Related Party Agreements With M

Related Party Agreements With Mikah Pharma LLC	12 Months Ended
	Mar. 31, 2019
Mikah Pharma LLC [Member]
RELATED PARTY AGREEMENTS WITH MIKAH PHARMA LLC	NOTE 22. RELATED PARTY AGREEMENTS WITH MIKAH PHARMA LLC Pursuant to an asset acquisition , On May 22, 2017, the Company executed an assignment agreement with Mikah, pursuant to which the Company acquired all rights, interests and obligations under a manufacturing and supply agreement with Epic originally entered into by Mikah on June 30, 2015 and relating to the manufacture and supply of Trimipramine (the "Epic Trimipramine Manufacturing Agreement"). Pursuant to this agreement, Epic manufactured Trimipramine under license from Elite. In September 2018, Elite successfully transferred manufacturing of Trimipramine to the Northvale Facility, resulting in the irrelevance of the Epic Trimipramine Manufacturing Agreement. Trimipramine is currently manufactured by Elite. Mikah is owned by Nasrat Hakim, the CEO, President and Chairman of the Board of the Company. The Reddy's Distribution Agreement was concluded by mutual consent in August 2018. Trimipramine is one of the products included in the Glenmark Strategic Alliance and is currently marketed and distributed by Glenmark.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 23. INCOME TAXES The components of the credit for income taxes are as follows: Years ended March 31, 2019 2018 Federal Current $ - $ - Deferred - - State Current 3,000 (5,500 ) Deferred - - Benefit from sale of state net operating loss credits 673,016 1,051,329 Net benefit from sale of state net operating loss credits $ 676,016 $ 1,045,829 The major components of deferred tax assets and liabilities at March 31, 2019 and 2018 are as follows (amounts in thousands of dollars): Years ended March 31, 2019 2018 Federal Net operating loss carry forward $ 21,005 $ 19,213 Valuation allowance (21,005 ) (19,213 ) $ - $ - State Net operating loss carry forward $ 2,239 $ 1,796 Valuation allowance (2,239 ) (1,796 ) $ - $ - At March 31, 2019 and 2018 a 100% valuation allowance is provided, as it is uncertain if the deferred tax assets will provide any future benefits because of the uncertainty about the Company's ability to generate the future taxable income necessary to use the net operating loss carryforwards. The company believes that temporary timing differences between accrual and payment of income taxes are not material to the financial position of the Company. As of March 31, 2019, Elite has a federal net operating loss carryforward of $100,024,740 and net operating loss carryforward in state tax jurisdictions of $24,873,437 some of which will begin to expire in 2020.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 24. SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through June 21, 2019. The following are material subsequent events: Common Stock issued and sold pursuant to the Lincoln Park Purchase Agreement Subsequent to March 31, 2019 and up to June 7, 2019 (the latest practicable date), a total of 3,541,942 shares of Common Stock were issued to Lincoln Park, with such shares consisting of 3,500,000 purchase shares and 41,942 additional commitment shares. Total proceeds from these transactions was $302,800.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying audited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and in conformity with the instructions on Form 10-K and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission ("SEC"). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elite Laboratories, Inc. All significant intercompany accounts and transactions have been eliminated in consolidation.
Going Concern	Going Concern At March 31, 2019, the Company had unrestricted cash balances totaling $2.3 million. The Company has incurred losses and negative cash flows from operations every year since its inception, including operating losses and negative overall cash flows of $9.1 million and $4.9 million for the year ended March 31, 2019, respectively. In addition, overall working capital, defined as current assets minus current liabilities decreased by approximately $6.6 million during the year ended March 31, 2019. Based on the foregoing, the Company has determined that there did appear to be evidence of substantial doubt of its ability to continue as a going concern. To continue as a going concern, the Company will need to do some or all of the following, without limitation: obtainment additional financing, increase sales of existing products, bring additional products in the pipe line to market and/or reduce expenses. the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements included herein do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.
Segment Information	Segment Information Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 280, Segment Reporting The Company has determined that its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Applications ("ANDA") and products whose marketing approvals were secured via a New Drug Application ("NDA"). ANDA products are referred to as generic pharmaceuticals and NDA products are referred to as branded pharmaceuticals. There are currently no intersegment revenues. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company's audited consolidated financial statements. Please see note 17 for further details.
Revenue Recognition	Revenue Recognition The Company generates revenue from the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, commercialization of products either by license and the collection of royalties, or through the manufacture of formulations and the development of new products and the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations. The Company also generates revenue through its focus on the development of various types of drug products, including branded drug products which require NDAs. Under ASC 606, Revenue from Contacts with Customers
Nature of goods and services	Nature of goods and services The following is a description of the Company's goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable: a) Manufacturing Fees The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if and when the products are approved. These products include products using controlled-release drug technology and products utilizing abuse deterrent technologies. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release and abuse deterrent pharmaceutical products. The Company recognizes revenue when the customer obtains control of the Company's product based on the contractual shipping terms of the contract. Revenue on product are presented gross because the Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. b) License Fees The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company's contracts contained a significant financing component as of December 31, 2018. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer's products occurs.
Disaggregation of revenue	Disaggregation of revenue In the following table, revenue is disaggregated by type of revenue generated by the Company and timing of revenue recognition. The table also includes a reconciliation of the disaggregated revenue with the reportable segments: For the year ended March 31, 2019 2018 NDA: Licensing fees $ 1,000,000 $ 1,000,000 Total NDA revenue 1,000,000 1,000,000 ANDA: Manufacturing fees $ 5,387,696 $ 5,199,006 Licensing fees 1,180,812 1,259,705 Total ANDA revenue 6,568,508 6,458,711 Total revenue $ 7,568,508 $ 7,458,711
Collaborative Arrangements	Collaborative Arrangements Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808, Collaborative Arrangements ● The parties to the contract must actively participate in the joint operating activity; and ● The joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. The Company entered into a sales and distribution licensing agreement with Epic Pharma LLC, dated June 4, 2015 (the " 2015 Epic License Agreement The Company entered into a Master Development and License Agreement with SunGen Pharma LLC dated August 24, 2016 (the " SunGen Agreement
Cash	Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market instruments. The Company places its cash and cash equivalents with high-quality, U.S. financial institutions and, to date has not experienced losses on any of its balances.
Restricted Cash	Restricted Cash As of March 31, 2019, and 2018, the Company had $398,125 and $391,566 of restricted cash, respectively, related to debt service reserve in regard to the New Jersey Economic Development Authority (“ NJEDA
Accounts Receivable	Accounts Receivable Accounts receivable are comprised of balances due from customers, net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances.
Inventory	Inventory Inventory is recorded at the lower of cost or market on a specific identification by lot number basis.
Long-Lived Assets	Long-Lived Assets The Company periodically evaluates the fair value of long-lived assets, which include property and equipment and intangibles, whenever events or changes in circumstances indicate that its carrying amounts may not be recoverable. Property and equipment are stated at cost. Depreciation is provided on the straight-line method based on the estimated useful lives of the respective assets which range from three to forty years. Major repairs or improvements are capitalized. Minor replacements and maintenance and repairs which do not improve or extend asset lives are expensed currently. Upon retirement or other disposition of assets, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is recognized in income.
Intangible Assets	Intangible Assets The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. Costs to acquire indefinite lived intangible assets, such as costs related to ANDAs are capitalized accordingly. The Company tests its intangible assets for impairment at least annually (as of March 31st) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company’s segments; unanticipated competition; and slower growth rates. As of March 31, 2019, the Company did not identify any indicators of impairment. Please also see Note 5 for further details on intangible assets.
Research and Development	Research and Development Research and development expenditures are charged to expense as incurred.
Leases	Leases Lease agreements are evaluated to determine if they are capital leases meeting any of the following criteria at inception: (a) transfer of ownership; (b) bargain purchase option; (c) the lease term is equal to 75 percent or more of the estimated economic life of the leased property; or (d) the present value at the beginning of the lease term of the minimum lease payments, excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, including any profit thereon, equals or exceeds 90 percent of the excess of the fair value of the leased property to the lessor at lease inception over any related investment tax credit retained by the lessor and expected to be realized by the lessor. If at its inception a lease meets any of the four lease criteria above, the lease is classified by the Company as a capital lease; and if none of the four criteria are met, the lease is classified by the Company as an operating lease. Please also see the section titled "Recently Issued Accounting Pronouncements" regarding accounting standards relating to leases that will be implemented effective as of April 1, 2019.
Contingencies	Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company's consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company operates in multiple tax jurisdictions within the United States of America. The Company remains subject to examination in all tax jurisdiction until the applicable statutes of limitation expire. As of March 31, 2019, a summary of the tax years that remain subject to examination in our major tax jurisdictions are: United States – Federal, 2014 and forward, and State, 2010 and forward. The Company did not record unrecognized tax positions for the years ended March 31, 2019 and 2018.
Warrants and Preferred Shares	Warrants and Preferred Shares The accounting treatment of warrants and preferred share series issued is determined pursuant to the guidance provided by ASC 470, Debt Distinguishing Liabilities from Equity Derivatives and Hedging
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation-Stock Compensation In accordance with the Company's Director compensation policy and certain employment contracts, director's fees and a portion of employee's salaries are to be paid via the issuance of shares of the Company's common stock, in lieu of cash, with the valuation of such share being calculated on a quarterly basis and equal to the simple average closing price of the Company's common stock.
Earnings (Loss) Per Share Applicable to Common Shareholders'	Earnings (Loss) Per Share Applicable to Common Shareholders' The Company follows ASC 260, Earnings Per Share The following is the computation of earnings (loss) per share applicable to common shareholders for the periods indicated: Years ended March 31, 2019 2018 Numerator Net loss attributable to common shareholders - basic $ (9,279,320 ) $ (3,673,172 ) Effect of dilutive instrument on net loss (180,042 ) (4,650,266 ) Net loss attributable to common shareholders - diluted $ (9,459,362 ) $ (8,323,438 ) Denominator Weighted average shares of common stock outstanding - basic 814,172,891 796,069,419 Dilutive effect of stock options, warrants and convertible securities 2,140,101 2,100,000 Weighted average shares of common stock outstanding - diluted 816,312,992 798,169,419 Net income (loss) per share Basic $ (0.01 ) $ (0.00 ) Diluted $ (0.01 ) $ (0.01 )
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows: ● Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 Inputs that are unobservable for the asset or liability. Measured on a Recurring Basis The following table presents information about our liabilities measured at fair value on a recurring basis as of March 31, 2019 and March 31, 2018, aggregated by the level in the fair value hierarchy within which those measurements fell: Amount at Fair Value Measurement Using Fair Value Level 1 Level 2 Level 3 March 31, 2019 Liabilities Derivative financial instruments - warrants $ 2,487,830 $ - $ - $ 2,487,830 March 31, 2018 Liabilities Derivative financial instruments - warrants $ 2,667,871 $ - $ - $ 2,667,871 See Note 12, for specific inputs used in determining fair value. The carrying amounts of the Company's financial assets and liabilities, such as cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate their fair values because of the short maturity of these instruments. Based upon current borrowing rates with similar maturities the carrying value of long-term debt approximates fair value. Non-Financial Assets that are Measured at Fair Value on a Non-Recurring Basis Non-financial assets such as intangible assets, and property and equipment are measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets in the periods presented.
Treasury Stock	Treasury Stock The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of shareholders' equity (deficit).
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-01, Business Combinations: Clarifying the Definition of a Business In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ● ASU No. 2015-14, “ Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date” ● ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ; ● ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ● ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting ● ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606):Narrow-Scope Improvements and Practical Expedients ● ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers These ASUs have generally been codified in Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” Accounting Standards Codification Topic 605, “Revenue Recognition” The Company adopted ASC 606 on April 1, 2018 for all open contracts and related amendments as of such date, using the modified retrospective method. Under the modified retrospective method, results beginning on April 1, 2018 are presented under ASC 606, while the comparative prior period(s) results continue to be presented under ASC 605, based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded no change in its accumulated deficit at April 1, 2018, representing the cumulative impact of adopting ASC 606. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 , Restricted Cash (ASC 230): Statement of Cash Flows (“ASU No. 2016-18”). In May 2017, the FASB issued ASU No 2017-09 Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (ASC 842) In January 2017, the FASB issued ASU No 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (ASC 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In March 2019, the FASB issued ASU 2019-1, Leases (Topic 842) Codification Improvements ● Determining the fair value of the underlying asset by lessors that are not manufacturers or dealers (Issue 1); ● Presentation on the statement of cash flows—sales-type and direct financing leases (Issue 2), and ● Transition disclosures related to Topic 250, Accounting Changes and Error Corrections (Issue 3). The amendments in ASU 2019-1 amend Topic 842 and are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is evaluating the effect that this update will have on its consolidated financial statements and related disclosures. Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of disaggregation of revenue	For the year ended March 31, 2019 2018 NDA: Licensing fees $ 1,000,000 $ 1,000,000 Total NDA revenue 1,000,000 1,000,000 ANDA: Manufacturing fees $ 5,387,696 $ 5,199,006 Licensing fees 1,180,812 1,259,705 Total ANDA revenue 6,568,508 6,458,711 Total revenue $ 7,568,508 $ 7,458,711
Schedule of earnings (loss) per share applicable to common shareholders	Years ended March 31, 2019 2018 Numerator Net loss attributable to common shareholders - basic $ (9,279,320 ) $ (3,673,172 ) Effect of dilutive instrument on net loss (180,042 ) (4,650,266 ) Net loss attributable to common shareholders - diluted $ (9,459,362 ) $ (8,323,438 ) Denominator Weighted average shares of common stock outstanding - basic 814,172,891 796,069,419 Dilutive effect of stock options, warrants and convertible securities 2,140,101 2,100,000 Weighted average shares of common stock outstanding - diluted 816,312,992 798,169,419 Net income (loss) per share Basic $ (0.01 ) $ (0.00 ) Diluted $ (0.01 ) $ (0.01 )
Schedule of liabilities measured at fair value on a recurring basis	Amount at Fair Value Measurement Using Fair Value Level 1 Level 2 Level 3 March 31, 2019 Liabilities Derivative financial instruments - warrants $ 2,487,830 $ - $ - $ 2,487,830 March 31, 2018 Liabilities Derivative financial instruments - warrants $ 2,667,871 $ - $ - $ 2,667,871

Asset Acquisition (Tables)

Asset Acquisition (Tables)	12 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Schedule of identifiable intangible asset	ANDA acquisition costs $ 1,200,000 Total assets acquired $ 1,200,000

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of inventory	March 31, March 31, Finished goods $ 575,699 $ 229,204 Work-in-progress 189,069 297,350 Raw materials 3,750,955 4,371,447 4,515,723 4,898,001 Less: Inventory reserve - - $ 4,515,723 $ 4,898,001

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	March 31, 2019 2018 Land, building and improvements $ 5,260,523 $ 5,260,524 Laboratory, manufacturing, warehouse and transportation equipment 12,078,340 11,715,805 Office equipment and software 373,601 176,965 Furniture and fixtures 383,103 249,393 18,095,567 17,402,687 Less: Accumulated depreciation (9,651,718 ) (8,408,979 ) $ 8,443,849 $ 8,993,708

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	March 31, 2019 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 465,684 $ - $ - $ - $ 465,684 ANDA acquisition costs Indefinite 7,247,317 - (1,078,966 ) - 6,168,351 $ 7,713,001 $ - $ (1,078,966 ) $ - $ 6,634,035 March 31, 2018 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 371,774 $ 93,910 $ - $ - $ 465,684 ANDA acquisition costs Indefinite 6,047,317 1,200,000 - - 7,247,317 $ 6,419,091 $ 1,293,910 $ - $ - $ 7,713,001 * Patent application costs were incurred in relation to the Company’s abuse deterrent opioid technology. Amortization of the patent costs will begin upon the issuance of marketing authorization by the FDA. Amortization will then be calculated on a straight-line basis through the expiry of the related patent(s).

NJEDA Bonds (Tables)

NJEDA Bonds (Tables)	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule bonds payable liability	March 31, March 31, Gross bonds payable NJEDA Bonds - Series A Notes $ 1,670,000 $ 1,760,000 Less: Current portion of bonds payable (prior to deduction of bond offering costs) (95,000 ) (90,000 ) Long-term portion of bonds payable (prior to deduction of bond offering costs) $ 1,575,000 $ 1,670,000 Bond offering costs $ 354,453 $ 354,453 Less: Accumulated amortization (192,591 ) (178,409 ) Bond offering costs, net $ 161,862 $ 176,044 Current portion of bonds payable - net of bond offering costs Current portions of bonds payable 95,000 $ 90,000 Less: Bonds offering costs to be amortized in the next 12 months (14,178 ) (14,178 ) Current portion of bonds payable, net of bond offering costs $ 80,822 $ 75,822 Long term portion of bonds payable - net of bond offering costs Long term portion of bonds payable 1,575,000 $ 1,670,000 Less: Bond offering costs to be amortized subsequent to the next 12 months (147,685 ) (161,866 ) Long term portion of bonds payable, net of bond offering costs $ 1,427,315 $ 1,508,134
Schedule of maturities of bonds for the next five years	Years ending March 31, Amount 2020 $ 95,000 2021 105,000 2022 110,000 2023 115,000 2024 125,000 Thereafter 1,120,000 $ 1,670,000

Loans Payable (Tables)

Loans Payable (Tables)	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of loans payable	March 31, March 31, Equipment and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between July 2019 and December 2023 $ 1,272,298 $ 1,201,861 Less: Current portion of loans payable (573,029 ) (578,841 ) Long-term portion of loans payable $ 699,269 $ 623,020
Schedule of loan principal payments	Years ending March 31, Amount 2020 $ 573,029 2021 260,358 2022 239,802 2023 162,111 2024 36,998 $ 1,272,298

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of the future minimum rental payments	Years ending March 31, Amount 2020 $ 220,650 2021 225,063 2022 229,563 2023 234,156 2024 238,836 Thereafter 681,240 $ 1,829,508

Mezzanine Equity (Tables)

Mezzanine Equity (Tables)	12 Months Ended
	Mar. 31, 2019
Schedule of authorized, issued and outstanding shares, along with carrying value and change in value	March 31, 2019 2018 Shares authorized 395.758 395.758 Shares outstanding - - Par value $ 0.01 $ 0.01 Stated value $ 100,000 $ 100,000 Conversion price $ 0.07 $ 0.07 Common Stock to be issued upon redemption - - Closing price on valuation date $ 0.10 $ 0.09 Carrying value of Series I convertible preferred stock $ - $ -
Schedule of key assumptions used in the monte carlo simulation	April 28, Fair value of the Company’s Common Stock $ 0.1521 Conversion price $ 0.1521 Number of Series J Preferred issued 24.0344 Fully diluted shares outstanding as of measurement date 923,392,780 Risk-free rate 2.30 % Volatility 90.00 % Shareholder approval threshold $ 0.1521 Probability of approval if ending stock price is greater than threshold - midpoint 82.50 % Probability of approval if ending stock price is greater than threshold - midpoint 17.50 % Trials 200,000
Series J Convertible preferred stock [Member]
Schedule of authorized, issued and outstanding shares, along with carrying value and change in value	March 31, March 31, Shares authorized 50.000 50.000 Shares outstanding 24.0344 24.0344 Par value $ 0.01 $ 0.01 Stated value $ 1,000,000 $ 1,000,000 Conversion price $ 0.1521 $ 0.1521 Common Stock to be issued upon conversion 158,017,321 158,017,321 Carrying value of Series J convertible preferred stock $ 13,903,960 $ 13,903,960

Derivative Financial Instrume_2

Derivative Financial Instruments - Warrants (Tables)	12 Months Ended
	Mar. 31, 2019
Derivative Liabilities Warrants Disclosure [Abstract]
Schedule of warrant activity	Year ended March 31, 2019 2018 Warrant Weighted Warrant Weighted Balance at beginning of year 79,008,661 $ 0.1521 9,379,219 $ 0.0625 Warrants granted pursuant to the issuance of Series J convertible preferred shares - $ - 79,008,661 $ 0.1521 Warrants exercised, forfeited and/or expired, net - $ - (9,379,219 ) $ 0.0625 Balance at end of year 79,008,661 $ 0.1521 79,008,661 $ 0.1521
Schedule of the fair value of the warrants issued prior to fiscal	March 31 Fair value of the Company's common stock $ 0.15 Volatility (based on the Company's historical volatility) 72.5% - 73.1 % Exercise price $ 0.0625 Estimated life (in years) 1.0 - 1.1 Risk free interest rate (based on 1-year treasury rate) 1.02% - 1.03 %
Schedule of key assumptions used in the monte carlo simulation	March 31, March 31, Fair value of the Company's Common Stock $ 0.990 $ 0.100 Initial exercise price $ 0.1521 $ 0.1521 Number of common warrants 79,008,661 79,008,661 Fully diluted shares outstanding as of measurement date 824,946,559 791,516,930 Warrant term (in years) 8.08 9.08 Risk-free rate 2.35 % 2.72 % Volatility 90.00 % 90.00 % Shareholder approval threshold $ 0.1580 $ 0.1580 Probability of approval if ending stock price is greater than threshold - midpoint 82.50 % 82.50 % Probability of approval if ending stock price is greater than threshold - midpoint 17.50 % 17.50 % Trials 100,000 100,000 Fair value of derivative financial instruments - warrants $ 2,487,830 $ 2,667,871
Schedule of changes in warrants measured at fair value on a recurring basis	Balance as of March 31, 2017 843,464 Fair value of warrants granted pursuant to the issuance of Series J convertible preferred shares 6,474,674 Change in fair value of derivative financial instruments - warrants (4,650,267 ) Balance as of March 31, 2018 $ 2,667,871 Change in fair value of derivative financial instruments - warrants (180,041 ) Balance as of March 31, 2019 $ 2,487,830

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) (Tables)	12 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Summary of Common Stock Activity	Years ended March 31, 2019 2018 Common Stock sold pursuant to the Lincoln Park Capital Purchase Agreements, with net proceeds of such shares totaling $2,063,541 and $1,999,878 for the years ended March 31, 2019 and 2018, respectively. 22,033,967 17,818,950 Common Stock issued as initial and additional commitment shares pursuant to the Lincoln Park Capital Purchase Agreements 285,831 5,817,560 Common Stock issued in payment of Director's fees totaling $0 and $80,000 for the years ended March 31, 2019 and 2018, respectively. - 645,496 Common Stock issued in payment of employee salaries totaling $0 and $305,000 for the years ended March 31, 2019 and 2018, respectively. - 2,460,941 Common Stock issued in payment of consulting expenses totaling $0 and $26,000 for the years ended March 31, 2019 and 2018, respectively. - 211,392 Common Stock issued pursuant to the exercise of cash warrants - 5,658,295 Common Stock Issued during the fiscal year 22,319,798 32,612,634 Retirement of Common Stock during the fiscal year - (158,017,321 ) Common Stock issued as of March 31, 2019 and 2018, respectively 824,946,559 802,626,761

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock option plan	Weighted Average Shares Weighted Average Exercise Remaining Contractual Aggregate Intrinsic Options Price (in years) Value Outstanding at March 31, 2017 6,737,667 $ 0.20 6.7 $ 258,747 Granted 640,000 0.16 Forfeited and expired - - Exercised (759,667 ) 0.56 Outstanding at March 31, 2018 6,618,000 $ 0.16 6.1 $ 90,390 Granted - Forfeited and expired (460,000 ) Exercised - Outstanding at March 31, 2019 6,158,000 $ 0.15 5.0 $ 87,330 Exercisable at March 31, 2019 5,635,002 $ 0.14 4.7 87,330
Schedule of fair value of the options using the Black-Scholes model	March 31, 2019 2018 Volatility (based on the Company's historical volatility) n/a 121% - 123 % Exercise price n/a $ 0.09 - 0.24 Estimated term (in years) n/a 10 Risk free interest rate (based on 1-year treasury rate) n/a 2.2% - 2.4 % Forfeiture rate n/a 0.0% - 20.1 % Fair value of options granted n/a $ 79,215 Non-cash compensation through issuance of stock options n/a $ 244,753

Segment Results (Tables)

Segment Results (Tables)	12 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of selected information for the Company’s reportable segments	Years ended March 31, 2019 2018 Revenue by Segment ANDA $ 6,568,508 $ 6,458,711 NDA 1,000,000 1,000,000 $ 7,568,508 $ 7,458,711 Years ended March 31, 2019 2018 Operating Income (Loss) by Segment ANDA $ (4,361,649 ) $ (1.827,943 ) NDA 122,961 (3,019,859 ) $ (4,238,688 ) $ (4,847,802 )
Schedule of operating loss by segment to (loss) income from operations	Years ended March 31, 2019 2018 Operating loss by segment $ (4,238,688 ) $ (4,847,802 ) Corporate unallocated costs (2,683,720 ) (2,234,264 ) Interest income 8,448 17,510 Interest expense and amortization of debt issuance costs (369,174 ) (335,498 ) Depreciation and amortization expense (1,206,495 ) (800,460 ) Significant non-cash items (1,645,750 ) (1,168,753 ) Change in fair value of derivative instruments 180,042 4,650,266 Income (loss) from operations before the benefit from sale of state net operating loss credits $ (9,955,337 ) $ (4,719,001 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of components of credit for income taxes	Years ended March 31, 2019 2018 Federal Current $ - $ - Deferred - - State Current 3,000 (5,500 ) Deferred - - Benefit from sale of state net operating loss credits 673,016 1,051,329 Net benefit from sale of state net operating loss credits $ 676,016 $ 1,045,829
Schedule of components of deferred tax assets and liabilities	Years ended March 31, 2019 2018 Federal Net operating loss carry forward $ 21,005 $ 19,213 Valuation allowance (21,005 ) (19,213 ) $ - $ - State Net operating loss carry forward $ 2,239 $ 1,796 Valuation allowance (2,239 ) (1,796 ) $ - $ -

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues	$ 7,568,508	$ 7,458,711
NDA [Member]
Revenues	1,000,000	1,000,000
NDA [Member] | Licensing fees [Member]
Revenues	1,000,000	1,000,000
ANDA [Member]
Revenues	6,568,508	6,458,711
ANDA [Member] | Licensing fees [Member]
Revenues	1,180,812	1,259,705
ANDA [Member] | Manufacturing fees [Member]
Revenues	$ 5,387,696	$ 5,199,006

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Numerator
Net loss attributable to common shareholders - basic	$ (9,279,321)	$ (3,673,172)
Effect of dilutive instrument on net loss	(180,042)	(4,650,266)
Net loss attributable to common shareholders - diluted	$ (9,459,362)	$ (8,323,438)
Denominator
Weighted average shares of common stock outstanding - basic	814,172,891	796,069,419
Dilutive effect of stock options, warrants and convertible securities	2,140,101	2,100,000
Weighted average shares of common stock outstanding - diluted	816,312,992	798,169,419
Net income (loss) per share
Basic	$ (0.01)	$ 0
Diluted	$ (0.01)	$ (0.01)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Derivative financial instruments - warrants	$ 2,487,830	$ 2,667,871
Level 1 [Member]
Derivative financial instruments - warrants
Level 2 [Member]
Derivative financial instruments - warrants
Level 3 [Member]
Derivative financial instruments - warrants	$ 2,487,830	$ 2,667,871

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Summary of Significant Accounting Policies (Textual)
Restricted cash	$ 398,125	$ 391,566
Lease agreements, description	(a) transfer of ownership; (b) bargain purchase option; (c) the lease term is equal to 75 percent or more of the estimated economic life of the leased property; or (d) the present value at the beginning of the lease term of the minimum lease payments, excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, including any profit thereon, equals or exceeds 90 percent of the excess of the fair value of the leased property to the lessor at lease inception over any related investment tax credit retained by the lessor and expected to be realized by the lessor.
Tax benefits, description	The largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Right-of-use asset, lease liability, description	The Company has evaluated the effets of ASU 2016-02 and determined that a right-of-use asset, lease liability and increase in accumulated deficit due to cumulative effect of change in accounting principal valued at approximately $1.1 million, $1.5 million and $0.3 million, respectively will be recorded as of April 1, 2019.
Un restricted cash balance	$ 2,300,000
Losses and negative cash flows from operations	(9,158,700)	(9,051,279)
Working capital	6,600,000
Accounting Standards Update 2016-18 [Member]
Summary of Significant Accounting Policies (Textual)
Increase in restricted cash	$ 391,566	$ 389,081	$ 388,959

Asset Acquisition (Details)

Asset Acquisition (Details) - ANDA products [Member]	Mar. 31, 2019USD ($)
ANDA acquisition costs	$ 1,200,000
Total assets acquired	$ 1,200,000

Asset Acquisition (Details Text

Asset Acquisition (Details Textual)	May 15, 2017USD ($)
Secured Promissory Note [Member]
Asset Acquisition (Textual)
Principal amount	$ 1,200,000

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Inventory Disclosure [Abstract]
Finished goods	$ 575,699	$ 229,204
Work-in-progress	189,069	297,350
Raw materials	3,750,955	4,371,447
Inventory, gross	4,515,723	4,898,001
Less: Inventory reserve
Inventory, net	$ 4,515,723	$ 4,898,001

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,095,567	$ 17,402,687
Less: Accumulated depreciation	(9,651,718)	(8,408,979)
Property and equipment, net	8,443,849	8,993,708
Land, building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,260,523	5,260,524
Laboratory, manufacturing, warehouse and transportation equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,078,340	11,715,805
Office equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	373,601	176,965
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 383,103	$ 249,393

Property and Equipment, Net (_2

Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property and Equipment, Net (Textual)
Depreciation expense	$ 1,242,739	$ 982,227

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		12 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 7,713,001	$ 6,419,091
Additions			1,293,910
Reductions		(1,078,966)
Accumulated Amortization		0	0
Net Book Value		$ 6,634,035	$ 7,713,001
Patent Application Cost [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	[1]	0 Years	0 Years
Gross Carrying Amount		$ 465,684	$ 371,774
Additions			93,910
Reductions
Accumulated Amortization
Net Book Value		$ 465,684	$ 465,684
ANDA Acquisition Cost [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life		Indefinite	Indefinite
Gross Carrying Amount		$ 7,247,317	$ 6,047,317
Additions			1,200,000
Reductions		(1,078,966)
Accumulated Amortization
Net Book Value		$ 6,168,351	$ 7,247,317
[1]	Patent application costs were incurred in relation to the Company's abuse deterrent opioid technology. Amortization of the patent costs will begin upon the issuance of marketing authorization by the FDA. Amortization will then be calculated on a straight-line basis through the expiry of the related patent(s).

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Intangible Assets (Textual)
Aggregate carrying amount discontinued	$ 291,491
Aggregate carrying amount transferred to Epic Pharma	787,475
Cash consideration	450,000
Additional annual fees in excess	1,100,000
Realized loss on transfer/discontinuance of intangible assets	628,966
ANDAs [Member]
Intangible Assets (Textual)
Aggregate carrying amount discontinued	1,078,966
Aggregate carrying amount transferred to Epic Pharma	$ 450,000

NJEDA Bonds (Details)

NJEDA Bonds (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Njeda Bonds [Line Items]
Less: Current portion of bonds payable	$ (80,822)	$ (75,822)
Long-term portion of bonds payable	1,427,315	1,508,134
Njeda Bonds Current [Member]
Njeda Bonds [Line Items]
Current portions of bonds payable	95,000	90,000
Less: Bond offering costs to be amortized	(14,178)	(14,178)
Current portion of bonds payable	80,822	75,822
Njeda Bonds Non-Current [Member]
Njeda Bonds [Line Items]
Long-term portion of bonds payable	1,427,315	1,508,134
Current portions of bonds payable	1,575,000	1,670,000
Less: Bond offering costs to be amortized	(147,685)	(161,866)
Njeda Bonds Series A Notes [Member]
Njeda Bonds [Line Items]
NJEDA Bonds - Series A Notes	1,670,000	1,760,000
Less: Current portion of bonds payable	(95,000)	(90,000)
Long-term portion of bonds payable	1,575,000	1,670,000
Bond offering costs	354,453	354,453
Less: Accumulated amortization	(192,951)	(178,409)
Bond offering costs, net	$ 161,862	$ 176,044

NJEDA Bonds (Details 1)

NJEDA Bonds (Details 1) - NJEDA Bonds [Member]	Mar. 31, 2019USD ($)
2020	$ 95,000
2021	105,000
2022	110,000
2023	115,000
2024	125,000
Thereafter	1,120,000
Total	$ 1,670,000

NJEDA Bonds (Details Textual)

NJEDA Bonds (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
NJEDA Bonds [Member]
Njeda Bonds (Textual)
Amortization of debt issuance costs	$ 14,178	$ 14,178
Series A Note [Member]
Njeda Bonds (Textual)
Debt instrument, interest rate during period	6.50%

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Debt Disclosure [Abstract]
Equipment and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between July 2019 and December 2023	$ 1,272,298	$ 1,201,861
Less: Current portion of loans payable	(573,029)	(578,841)
Long-term portion of loans payable	$ 699,269	$ 623,020

Loans Payable (Details 1)

Loans Payable (Details 1) - Loans Payable [Member]	Mar. 31, 2019USD ($)
Years ending March 31,
2020	$ 573,029
2021	260,358
2022	239,802
2023	162,111
2024	36,998
Total Loan principal payments	$ 1,272,298

Loans Payable (Details Textual)

Loans Payable (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Debt Instrument [Line Items]
Interest expense, debt	$ 114,980	$ 119,890
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	12.73%
Maturity date	Dec. 31, 2023
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.50%
Maturity date	Jul. 31, 2019

Related Party Secured Promiss_2

Related Party Secured Promissory Note With Mikah Pharma LLC (Details) - USD ($)	May 15, 2017	Mar. 31, 2019	Mar. 31, 2018
Related Party Secured Promissory Note With Mikah Pharma LLC (Textual)
Interest expense, total		$ 369,173	$ 335,498
Mikha Pharma LLC [Member]
Related Party Secured Promissory Note With Mikah Pharma LLC (Textual)
Interest payable		225,000
Secured Promissory Note [Member]
Related Party Secured Promissory Note With Mikah Pharma LLC (Textual)
Debt instrument default, interest rate percentage	15.00%
Debt instrument, face amount	$ 1,200,000
Debt instrument, maturity date	Dec. 31, 2020
Debt instrument, interest rate, stated percentage	10.00%
Interest expense, total		$ 120,000

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Deferred Revenue (Textual)
Deferred revenues	$ 1,252,223	$ 2,265,557
Deferred revenues current component	1,013,333	1,013,333
Deferred revenues long-term component	$ 238,890	$ 1,252,223
Licensing Agreements [Member]
Deferred Revenue (Textual)
Deferred revenues term, description	Straight-line basis.
TAGI licensing agreement [Member]
Deferred Revenue (Textual)
Deferred revenues term, description	Fifteen-year term beginning in September 2010 and ending in August 2025.
Advance payment of deferred revenue	$ 200,000
Epic Collaborative Agreement [Member]
Deferred Revenue (Textual)
Deferred revenues term, description	Five-year term beginning in June 2015 and ending in May 2020.
Advance payment of deferred revenue	$ 5,000,000

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 220,650
2021	225,063
2022	229,563
2023	234,156
2024	238,836
Thereafter	681,240
Total future minimum lease payment	$ 1,829,508

Commitments and Contingencies_3

Commitments and Contingencies (Details Textual)	12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Jul. 31, 2014a	Jul. 01, 2010a
Commitments and Contingencies (Textual)
Operating lease, terms	Lease includes an initial term, which expires on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.
General and Administrative Expense [Member]
Commitments and Contingencies (Textual)
Rent expense	$ 219,638	$ 219,636
Other Noncurrent Liabilities [Member]
Commitments and Contingencies (Textual)
Deferred rent	13,022	9,702
Other long-term liabilities	$ 33,383	$ 31,443
Warehouse [Member] | Property Subject to Operating Lease [Member]
Commitments and Contingencies (Textual)
Building floor space | a				15,000
Warehouse [Member] | Property Subject to Operating Lease [Member] | July 2014 Modification Agreement [Member]
Commitments and Contingencies (Textual)
Building floor space | a			35,000

Mezzanine Equity (Details)

Mezzanine Equity (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2016
Series J Convertible preferred stock [Member]
Shares authorized	50	50
Shares outstanding	24.0344	24.0344
Par value	$ 0.01	$ 0.01
Stated value	$ 1,000,000	$ 1,000,000
Conversion price		$ 0.1521
Common Stock to be issued upon conversion	158,017,321	158,017,321
Carrying value of Series I & J convertible preferred stock	$ 13,903,960	$ 13,903,960
Series I Convertible Preferred Stock [Member]
Shares authorized	395.758	395.758	495.758
Shares outstanding		0
Par value	$ 0.01	$ 0.01	$ 0.01
Stated value	$ 100,000	$ 100,000	$ 10,000,000
Conversion price	$ 0.07	$ 0.07
Common Stock to be issued upon redemption
Closing price on valuation date	$ 0.1	$ 0.09
Carrying value of Series I & J convertible preferred stock

Mezzanine Equity (Details 1)

Mezzanine Equity (Details 1) - Series J Convertible preferred stock [Member]	1 Months Ended
	Apr. 28, 2017$ / sharesshares
Fair value of the Company's Common Stock | $ / shares	$ 0.1521
Conversion price | $ / shares	$ 0.1521
Number of Series J Preferred issued | shares	24.0344
Fully diluted shares outstanding as of measurement date | shares	923,392,780
Shareholder approval threshold | $ / shares	0.1521
Trials | shares	200,000
Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions percentage	2.30%
Measurement Input, Price Volatility [Member]
Fair value assumptions percentage	90.00%
Measurement Input, Default Rate [Member] | Maximum [Member]
Fair value inputs probability percentage	82.50%
Measurement Input, Default Rate [Member] | Minimum [Member]
Fair value inputs probability percentage	17.50%

Mezzanine Equity (Details Textu

Mezzanine Equity (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 16, 2016	Mar. 31, 2018	Mar. 31, 2019	Apr. 28, 2017	Mar. 31, 2016
Convertible Preferred Stock [Member]
Mezzanine Equity (Textual)
Preferred stock share authorized		395.758
Preferred stock conversion price per share	$ 0.07
Conversion of stock, shares converted	100
Conversion of stock, shares issued	142,857,143
Series J Convertible preferred stock [Member]
Mezzanine Equity (Textual)
Preferred stock share authorized		50	50
Preferred stock shares issued		24.0344
Preferred stock shares outstanding		24.0344	24.0344
Convertible preferred stock par value per share		$ 0.01	$ 0.01
Convertible preferred stock stated value		$ 1,000,000	$ 1,000,000
Preferred stock conversion price per share		$ 0.1521
Shares of common stock		158,017,321
Percentage of devidend rate		20.00%
Preferred stock par value		$ 0.01
Series J Convertible preferred stock [Member] | Nasrat Hakim [Member]
Mezzanine Equity (Textual)
Warrants to purchase				79,008,661
Shares of common stock per share				$ 0.1521
Series I Convertible Preferred Stock [Member]
Mezzanine Equity (Textual)
Preferred stock share authorized		395.758	395.758		495.758
Preferred stock shares issued					100
Preferred stock shares outstanding		0
Convertible preferred stock par value per share		$ 0.01	$ 0.01		$ 0.01
Convertible preferred stock stated value		$ 100,000	$ 100,000		$ 10,000,000
Preferred stock conversion price per share		$ 0.07	$ 0.07

Derivative Financial Instrume_3

Derivative Financial Instruments - Warrants (Details) - $ / shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative Liabilities Warrants Disclosure [Abstract]
Warrants, Balance at beginning of year	79,008,661	9,379,219
Warrants granted pursuant to the issuance of Series J convertible preferred shares		79,008,661
Warrants exercised, forfeited and/or expired, net		(9,379,219)
Warrants, Balance at end of year	79,008,661	79,008,661
Weighted Average Exercise Price, Balance at beginning of year	$ 0.1521	$ 0.0625
Warrants granted pursuant to the issuance of Series J convertible preferred shares		0.1521
Weighted Average Exercise Price, Warrants exercised, forfeited and/or expired, net		0.0625
Weighted Average Exercise Price, Ending Balance	$ 0.1521	$ 0.1521

Derivative Financial Instrume_4

Derivative Financial Instruments - Warrants (Details 1) - $ / shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Maximum [Member]
Fair value of the Company’s common stock	$ 0.10
Warrant [Member]
Fair value of the Company’s common stock			$ 0.15
Volatility (based on the Company’s historical volatility)	90.00%	90.00%
Exercise price			$ 0.0625
Risk free interest rate (based on 1-year treasury rate)	2.35%	2.72%
Warrant [Member] | Minimum [Member]
Volatility (based on the Company’s historical volatility)			72.50%
Estimated life (in years)			1 year
Risk free interest rate (based on 1-year treasury rate)			1.02%
Warrant [Member] | Maximum [Member]
Volatility (based on the Company’s historical volatility)			73.10%
Estimated life (in years)			1 year 1 month 6 days
Risk free interest rate (based on 1-year treasury rate)			1.03%

Derivative Financial Instrume_5

Derivative Financial Instruments - Warrants (Details 2) - Warrant [Member] - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Fair value of the company's Common Stock	$ 0.990	$ 0.100
Initial exercise price	$ 0.1521	$ 0.1521
Number of common warrants	79,008,661	79,008,661
Fully diluted shares outstanding as of measurement date	824,946,559	791,516,930
Warrant term (in years)	8 years 29 days	9 years 29 days
Risk-free rate	2.35%	2.72%
Volatility	90.00%	90.00%
Shareholder approval threshold	0.1580	0.1580
Trials	100,000	100,000
Fair value of derivative financial instruments - warrants	$ 2,487,830	$ 2,667,871
Minimum [Member]
Risk-free rate			1.02%
Volatility			72.50%
Probability of approval if ending stock price is greater than threshold - midpoint	17.50%	17.50%
Maximum [Member]
Risk-free rate			1.03%
Volatility			73.10%
Probability of approval if ending stock price is greater than threshold - midpoint	82.50%	82.50%

Derivative Financial Instrume_6

Derivative Financial Instruments - Warrants (Details 3) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Balance as of March 31, 2018	$ 2,667,871
Balance as of December 31, 2018	2,487,830	$ 2,667,871
Level 3 [Member]
Balance as of March 31, 2018	2,667,871
Balance as of December 31, 2018	2,487,830	2,667,871
Warrants [Member] | Level 3 [Member]
Balance as of March 31, 2018	2,667,871	843,464
Fair value of warrants granted pursuant to the issuance of Series J convertible preferred shares		6,474,674
Change in fair value of derivative financial instruments - warrants	(180,041)	(4,650,267)
Balance as of December 31, 2018	$ 2,487,830	$ 2,667,871

Derivative Financial Instrume_7

Derivative Financial Instruments - Warrants (Details Textual)	1 Months Ended
	Apr. 28, 2017USD ($)$ / sharesshares
Derivative Financial Instruments - Warrants (Textual)
Warrant expiration period	10 years
Chief Executive Officer [Member]
Derivative Financial Instruments - Warrants (Textual)
Conversion of stock, shares issued	24.0344
Warrant shares	79,008,661
Conversion of stock, shares converted	158,017,321
Series J Convertible preferred stock [Member]
Derivative Financial Instruments - Warrants (Textual)
Fair value of the warrants | $	$ 6,474,674
Series J Warrant [Member]
Derivative Financial Instruments - Warrants (Textual)
Initial exercise price | $ / shares	$ 0.1521

Shareholders' Equity (Deficit_2

Shareholders' Equity (Deficit) (Details) - Common Stock [Member] - shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Common Stock sold pursuant to the Lincoln Park Capital Purchase Agreements, with net proceeds of such shares totaling $2,063,541 and $1,999,878 for the years ended March 31, 2019 and 2018, respectively.	22,033,967	17,818,950
Common Stock issued as initial and additional commitment shares pursuant to the Lincoln Park Capital Purchase Agreements	285,831	5,817,560
Common Stock issued in payment of Director’s fees totaling $0 and $80,000 for the years ended March 31, 2019 and 2018, respectively.		645,496
Common Stock issued in payment of employee salaries totaling $0 and $305,000 for the years ended March 31, 2019 and 2018, respectively.		2,460,941
Common Stock issued in payment of consulting expenses totaling $0 and $26,000 for the years ended March 31, 2019 and 2018, respectively.		211,392
Common Stock issued pursuant to the exercise of cash warrants		5,658,295
Common Stock Issued during the fiscal year	22,319,798	32,612,634
Retirement of Common Stock during the fiscal year		(158,017,321)
Common Stock issued as of March 31, 2019 and 2018, respectively	824,946,559	802,626,761

Shareholders' Equity (Deficit_3

Shareholders' Equity (Deficit) (Details Textual) - USD ($)	Jun. 05, 2017	May 01, 2017	Apr. 10, 2014	Mar. 31, 2019	Mar. 31, 2018
Class of Stock [Line Items]
Shares, value				$ 2,063,536	$ 1,999,878
Proceeds from issuance stock				$ 2,092,265	1,999,878
Common stock traded percent				30.00%
Common stock weighted average price percent				97.00%
Common Stock issued in payment of Directors' Fees				$ 0	80,000
Common Stock issued in payment of employee salaries				0	305,000
Common Stock issued in payment of consulting expenses				0	26,000
Lincoln Park Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase of common stock, amount				$ 2,063,541	1,999,878
Maximum [Member]
Class of Stock [Line Items]
Purchase of common stock, Shares				800,000
Share price				$ 0.10
Additional Paid-in Capital [Member]
Class of Stock [Line Items]
Shares, value				$ 2,041,502	1,982,059
Common Stock [Member]
Class of Stock [Line Items]
Shares, value				$ 22,034	$ 17,819
Common stock issued, Shares				32,612,634	216,487,096
Conversion of common stock amount				$ 0	$ 0
Lincoln Park [Member]
Class of Stock [Line Items]
Shares, value				$ 760,000
Shares, issued				40,000,000
Purchase of common stock, Shares				22,033,967	17,818,950
Purchase of common stock, amount				$ 2,063,541	$ 1,999,878
Common stock additional shares issued				285,831	5,540,551
Description of sale of stock				The Company, from time to time and at the Company's sole discretion but no more frequently than every other business day, could direct Lincoln Park to purchase (a "Regular Purchase") up to 500,000 shares of common stock on any such business day, increasing up to 800,000 shares, depending upon the closing sale price of the common stock, provided that in no event shall Lincoln Park purchase more than $760,000 worth of common stock on any single business day. The purchase price of shares of common stock related to the future Regular Purchase funding will be based on the prevailing market prices of such shares at the time of sales (or over a period of up to ten business days leading up to such time), but in no event, will shares be sold to Lincoln Park on a day the Common Stock closing price is less than the floor price of $0.10 per share, subject to adjustment.
Lincoln Park Capital Fund, LLC [Member]
Class of Stock [Line Items]
Shares, issued	40,000,000	5,540,551	40,000,000	1,928,641
Additional shares issued				1,928,641
Proceeds from issuance stock				$ 27,000,000
Common stock shares		500,000		500,000
Purchase of common stock increasing shares per purchase		1,000,000
Maximum common stock value directed to purchase		$ 1,000,000
Maximum percentage to purchase common stock shares				10.00%
Purchase of common stock, Shares				110,600,000
Common stock additional shares issued		5,540,551
Stock issued during period, shares, issued for capital purchase agreement				3,200,000
Common stock floor price per share				$ 0.10
Common stock weighted average price percent		4.99%
Description of sale of stock		The Company has the right to sell to and Lincoln Park is obligated to purchase up to $40 million in shares of common stock, subject to certain limitations, from time to time, over the 36-month period commencing on June 5, 2017. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 500,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase, increasing to up to 1,000,000 shares, depending upon the closing sale price of the common stock (such purchases, "Regular Purchases"). However, in no event shall a Regular Purchase be more than $1,000,000.	The Company entered into a Purchase Agreement (the "Lincoln Park Purchase Agreement" and/or "Purchase Agreement") and a Registration Rights Agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"). Pursuant to the terms of the Purchase Agreement, Lincoln Park has agreed to purchase from the Company up to $40 million of common stock (subject to certain limitations) from time to time over a 36-month period ending June 1, 2017. Pursuant to the terms of the Registration Rights Agreement, the Company filed with the SEC registration statements to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement. The latest registration statement, which updates the prior registration statements, was declared effective by the SEC on July 13, 2016.

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Equity [Abstract]
Shares Underlying Options, Outstanding at Beginning	6,618,000	6,737,667
Shares Underlying Options, Granted		640,000
Shares Underlying Options, Forfeited and expired	(460,000)
Shares Underlying Options, Outstanding at Ending	6,158,000	6,618,000
Shares Underlying Options, Exercised	5,635,002	(759,667)
Weighted Average Exercise Price, Outstanding at Beginning	$ 0.16	$ 0.20
Weighted Average Exercise Price, Options Granted		0.16
Weighted Average Exercise Price, Options Forfeited and expired
Weighted Average Exercise Price, Outstanding at Ending	0.15	0.16
Weighted Average Exercise Price, Options Exercised	$ 0.14	$ 0.56
Weighted Average Remaining Contractual Term (in years), Outstanding	5 years	6 years 1 month 6 days
Weighted Average Remaining Contractual Term (in years), Exercisable	4 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 87,330	$ 90,390
Aggregate Intrinsic Value, Exercisable	$ 87,330

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Expected volatility, Minimum		121.00%
Expected volatility, Maximum		123.00%
Estimated term (in years)		10 years
Risk-free interest rate, Minimum		2.20%
Risk-free interest rate, Maximum		2.40%
Fair value of options granted		$ 79,215
Non-cash compensation through issuance of stock options	$ 136,369	$ 244,753
Minimum [Member]
Exercise price		$ 0.09
Forfeiture rate		0.00%
Maximum [Member]
Exercise price		$ 0.24
Forfeiture rate		20.10%

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of common stock			80,000	73,361
Noninterest expense directors fees			$ 305,000
Price difference between exercise price and quoted price	$ 0.10	$ 0.10	$ 0.10	$ 0.10
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Noninterest expense directors fees	$ 75,000
Shares for payment of directors fees outstanding	793,617		793,617
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of common stock			645,496	334,295
Noninterest expense directors fees			$ 305,000	$ 76,250
Shares for payment of directors fees outstanding	3,338,871	695,348	3,338,871	695,348
Common Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Noninterest expense directors fees		$ 15,000	$ 60,000
Shares for payment of directors fees outstanding	656,827	136,790	656,827	136,790
Common Stock [Member] | Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based Employee Compensation, description			The Company accrued a total of 10,648,343 shares of common stock as being due and owing to its Chief Executive Officer and relating to accrued salaries in the aggregate amount of $1,125,000 earned, but not paid during the period January 1, 2017 through March 31, 2019. Of this amount, 5,473,559 shares was accrued for salaries totaling $500,000 for the 12 months ended March 31, 2019, 4,329,661 shares was accrued for salaries totaling $500,000 for the 12 months ended March 31, 2018 and 845,083 shares was accrued for salaries totaling $125,000 for the 3 month period ended March 31, 2017. Issuance of these shares has been deferred to an undetermined date.
Common Stock [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Noninterest expense directors fees			$ 381,250
Shares for payment of directors fees outstanding	4,034,219		4,034,219

Sale of New Jersey State Net _2

Sale of New Jersey State Net Operating Losses (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Sale of New Jersey State Net Operating Losses (Textual)
Net tax benefits	$ (676,016)	$ (1,045,829)
R&D tax credits [Member]
Sale of New Jersey State Net Operating Losses (Textual)
Net tax benefits	376,133	606,516
NJEDA [Member]
Sale of New Jersey State Net Operating Losses (Textual)
Net tax benefits	$ 296,883	$ 439,313
Net tax benefits, description	The Company sold the net tax benefits approved for sale at a transfer price equal to ninety-two cents for every benefit dollar for total proceeds of $619,175.	The Company sold the net tax benefits approved for sale at a transfer price equal to ninety-two cents for every benefit dollar for total proceeds of $1,045,829.

Concentrations and Credit Risk

Concentrations and Credit Risk (Details)	12 Months Ended
	Mar. 31, 2019SuppliersCustomers	Mar. 31, 2018SuppliersCustomers
Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	57.00%	52.00%
Number of customers	4	4
Sales Revenue, Net [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	22.00%	24.00%
Number of customers	4	4
Sales Revenue, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	9.00%	15.00%
Number of customers	4	4
Sales Revenue, Net [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	8.00%	8.00%
Number of customers	4	4
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	38.00%	52.00%
Number of customers	4	4
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	34.00%	14.00%
Number of customers	4	4
Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	19.00%	12.00%
Number of customers	4	4
Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	4.00%	11.00%
Number of customers	4	4
Cost of Goods, Total [Member] | Supplier [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	60.00%
Number of customers | Suppliers	3
Cost of Goods, Total [Member] | Supplier One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	35.00%	29.00%
Number of customers | Suppliers	3	3
Cost of Goods, Total [Member] | Supplier Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	27.00%
Number of customers | Suppliers	3	3
Cost of Goods, Total [Member] | Supplier Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%	5.00%
Number of customers | Suppliers	3	3

Segment Results (Details)

Segment Results (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Loss by Segment
Revenue by Segment	$ 7,568,508	$ 7,458,711
Operating Income (Loss) by Segment	(9,158,700)	(9,051,279)
ANDA [Member]
Operating Loss by Segment
Revenue by Segment	6,568,508	6,458,711
Operating Income (Loss) by Segment	(4,361,649)	(1,827,943)
NDA [Member]
Operating Loss by Segment
Revenue by Segment	1,000,000	1,000,000
Operating Income (Loss) by Segment	122,961	(3,019,859)
Business Segment [Member]
Operating Loss by Segment
Revenue by Segment	7,568,508	7,458,711
Operating Income (Loss) by Segment	$ (4,238,688)	$ (4,847,802)

Segment Results (Details 1)

Segment Results (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating loss by segment	$ (9,158,700)	$ (9,051,279)
Interest income	21,461	17,510
Depreciation and amortization expense	(1,206,495)	(800,460)
Income (loss) from operations before the benefit from sale of state net operating loss credits	(9,955,337)	(4,719,001)
Business Segment [Member]
Operating loss by segment	(4,238,688)	(4,847,802)
Corporate unallocated costs	(2,683,720)	(2,234,264)
Interest income	8,448	17,510
Interest expense and amortization of debt issuance costs	(369,174)	(335,498)
Depreciation and amortization expense	(1,206,495)	(800,460)
Significant non-cash items	(1,645,750)	(1,168,753)
Change in fair value of derivative instruments	180,042	4,650,266
Income (loss) from operations before the benefit from sale of state net operating loss credits	$ (9,955,337)	$ (4,719,001)

Collaborative Agreement with _2

Collaborative Agreement with Epic Pharma LLC (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jan. 31, 2016	Jun. 30, 2015	Mar. 31, 2019
Collaborative Arrangement [Member]
Collaborative Agreement with Epic Pharma LLC (Textual)
Revenues recognition milestone method, description			On June 4, 2015, the Company entered into the 2015 Epic License Agreement, which provides for the exclusive right to market, sell and distribute, by Epic Pharma LLC (“Epic”) of SequestOx™, an abuse deterrent opioid which employs the Company’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for payment of product development and pharmacovigilance costs, sales, and marketing of SequestOx™, and Elite will be responsible for the manufacture of the product. Under the 2015 Epic License Agreement, Epic will pay Elite non-refundable payments totaling $15 million, with such amount representing the cost of an exclusive license to ELI-200, the cost of developing the product and certain filings and a royalty based on an amount equal to 50% of profits derived from net product sales as defined in the 2015 Epic License Agreement. The initial term of the exclusive right to product development sales and distribution is five years (“Epic Exclusivity Period”); the license is renewable upon mutual agreement at the end of the initial term.
Elite received non-refundable payments totaling		$ 5,000,000
Epic License Agreement [Member]
Collaborative Agreement with Epic Pharma LLC (Textual)
Received payments totaling			$ 7,500,000
Non-refundable milestone	$ 2,500,000
License fees based on commercial sales			7,500,000
Non receipt remaining milestone			$ 7,500,000

Related Party Transaction Agr_2

Related Party Transaction Agreements with Epic Pharma LLC (Details)	12 Months Ended
	Mar. 31, 2019USD ($)
Epic License Agreement [Member]
Related Party Transaction Agreements with Epic Pharma LLC (Textual)
Milestone payments	$ 10,000,000
Description of related party transactions	On January 14, 2016, the Company filed an NDA with the FDA for SequestOx™, thereby earning a $2.5 million milestone pursuant to the 2015 Epic License Agreement. The Company has received payment of this amount from Epic. An additional $7.5 million is due upon approval by the FDA of the NDA filed for SequestOx™. Please note that on July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx™ NDA is complete and the application is not ready for approval in its present form. On December 21, 2016, the Company met with the FDA for an end-of-review meeting to discuss steps that it could take to obtain approval of SequestOx™. Based on this and the meeting minutes received from the FDA on January 23, 2017, the Company formulated a plan to address the issues cited by the FDA in the CRL, with such plan including, without limitation, modifying the SequestOx™ formulation, conducting bioequivalence and bioavailability fed and fasted studies, comparing the modified formulation to the original formulation. On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for SequestOx™. This study resulted in a mean Tmax of 4.6 hours, with a range of 0.5 hour to 12 hours and a mean Tmax of the comparator, Roxicodone® of 3.4 hours with a range of 0.5 hour to 12 hours. A key objective of this study was to determine if the reformulated SequestOx™ had a similar Tmax to the comparator when taken with a high fat meal. Based on these results, the Company will pause, not proceed, with the rest of the clinical trials, and seek clarity from the FDA before deciding on the next steps for immediate release SequestOx™. There can be no assurances of the success of any future clinical trials, or if such trials are successful, there can be no assurances that an intended future resubmission of the NDA product filing, if made, will be accepted by or receive marketing approval from the FDA, and accordingly, there can be no assurances that the Company will earn and receive the additional $7.5 million or future license fees.
Epic Generic Agreement [Member]
Related Party Transaction Agreements with Epic Pharma LLC (Textual)
Related party transaction amount	$ 1,800,000
Description of related party transactions	Elite was to receive $1.8 million, payable in increments that require the commercialization of all six exclusive products if the full amount is to be received, plus license fees equal to a percentage that is not less than 50% and not greater than 60% of profits achieved from commercial sales of the products, as defined in the Epic Generic Agreement. The Epic Generic Agreement expired on October 2, 2018 with Epic launching four of the six exclusive products and Elite collecting $1.0 million of the total $1.8 million fee.
Epic Pharma LLC [Member]
Related Party Transaction Agreements with Epic Pharma LLC (Textual)
Milestone payments	$ 2,500,000

Manufacturing, License and De_2

Manufacturing, License and Development Agreements (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Manufacturing, License and Development Agreements (Textual)
Revenues Recognition Milestone Method Milestone, Description	The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 & 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
Revenues	$ 7,568,508	$ 7,458,711
Glenmark Alliance [Member]
Manufacturing, License and Development Agreements (Textual)
Revenues Recognition Milestone Method Milestone, Description	The Glenmark Alliance, provides for the manufacture by Elite and marketing by Glenmark of identified generic products under license from Elite. In addition to the purchase prices for the products, Elite will receive license fees well in excess of 50% of gross profits. Gross profit is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. Glenmark will have semi-exclusive marketing rights to the ANDA approved generic product, phendimetrazine 35mg tablets, and exclusive marketing rights to generic Methadone HCl. Collectively, the brand products and their generic equivalents had total annual sales of approximately $33.6 million in 2017, according to Quintiles IMS Health data. The Agreement has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Glenmark to terminate with regard to a product on at least three months' prior written notice if it determines to stop marketing and selling such product, and it permits Elite to terminate with regard to a product if at any time after the first twelvemonths from the first commercial sale, the average license fee paid by Glenmark for such product is less than $100,000 for a six-month sales period.
Lannett-SunGen Product Alliance [Member]
Manufacturing, License and Development Agreements (Textual)
Revenues Recognition Milestone Method Milestone, Description	The Lannett-SunGen Product Alliance has an initial term of three years and automatically renews for one year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months’ prior written notice, and it permits Elite or Lannett to terminate with regard to a product if at anytime after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period. In addition to manufacturing fees and license fees, Lannett will also pay a milestone, of $750,000 upon commercial launch of the extended release CNS stimulant product that is currently under review by the FDA. This milestone payment will be shared equally by Elite and Sungen, pursuant to the Sungen Agreement.
Lannett-Elite Product Alliance [Member]
Manufacturing, License and Development Agreements (Textual)
Revenues Recognition Milestone Method Milestone, Description	The Lannett-Elite Product Alliance has an initial term of three years and automatically renews for one year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months’ prior written notice and it permits Elite or Lannett to terminate with regard to a product if at anytime after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period.
Collaborative Arrangement [Member]
Manufacturing, License and Development Agreements (Textual)
Revenues Recognition Milestone Method Milestone, Description	The Precision Dose Agreement provides for the marketing and distribution, by Precision Dose and its wholly owned subsidiary, TAGI Pharma, of Phentermine 37.5mg tablets (launched in April 2011), Phentermine 15mg capsules (launched in April 2013), Phentermine 30mg capsules (launched in April 2013), Hydromorphone 8mg tablets (launched in March 2012), Naltrexone 50mg tablets (launched in September 2013).
Revenues	$ 200,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Federal
Current
Deferred
State
Current	3,000	(5,500)
Deferred
Benefit from sale of state net operating loss credits	673,016	1,051,329
Net benefit from sale of state net operating loss credits	$ 676,016	$ 1,045,829

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Federal
Net operating loss carry forward	$ 21,005	$ 19,213
Valuation allowance	(21,005)	(19,213)
Deferred tax assets and liabilities
State
Net operating loss carry forward	2,239	1,796
Valuation allowance	(2,239)	(1,796)
Deferred tax assets and liabilities

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Taxes (Textual)
Valuation allowance percentage	100.00%	100.00%
Operating loss expire date	Mar. 31, 2020
Federal [Member]
Income Taxes (Textual)
Operating Loss Carryforwards	$ 100,024,740
State Tax Jurisdictions [Member]
Income Taxes (Textual)
Operating Loss Carryforwards	$ 24,873,437

Subsequent Events (Details)

Subsequent Events (Details) - Lincoln Park Capital Fund, LLC [Member]	12 Months Ended
	Mar. 31, 2019shares
Subsequent Events (Textual)
Subsequent event, description	Subsequent to March 31, 2019 and up to June 7, 2019 (the latest practicable date), a total of 3,541,942 shares of Common Stock were issued to Lincoln Park, with such shares consisting of 3,500,000 purchase shares and 41,942 additional commitment shares. Total proceeds from these transactions was $302,800.
Proceeds from issuance of common stock	3,500,000